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Résumé 
/¶DGGLFWLRQ DX[ GURJXHV HVW XQH PDODGLH PXOWLIDFWRULHOOH DIIHFWDQW WRXWes les strates de notre société. 
Cependant, la vulnérabilité à développer une addiction dépend de facteurs environnementaux, génétiques et 
SV\FKRVRFLDX[/¶DGGLFWLRQDX[GURJXHVHVW décrite comme étant une maladie chronique avec un taux élevé 
de rechutes. Elle se caractérise par un besoin irrépressible de consommer une drogue et une augmentation 
progressive de la consommation en dépit des conséquences néfastes. Les mécanismes cérébraux 
responsables des dépendances aux drogues ne sont que partiellement élucidés, malgré une accumulation 
croissaQWHG¶pYLGHQFHVGpPRQWUDQWdes adaptations au niveau moléculaire et cellulaire au sein des systèmes 
GRSDPLQHUJLTXHHWJOXWDPDWHUJLTXH/¶LGHQWLILFDWLRQGHQRXYHDX[ IDFWHXUVQHXURELRORJLTXHV UHVSRQVDEOHV
GH OD YXOQpUDELOLWp DX[ VXEVWDQFHV G¶DEXV HVW FUXFLDOe pour le développement de nouveaux traitements 
thérapeutiques capables G¶DWWpQXHUHWGHVRXODJHU les symptômes liés à la dépendance aux drogues. 
Au cours des dernières années, de nombreuses études ont démontré qu¶XQ QRXYHDX FLUFXLW FpUpEUDO le 
système hypocrétinergique, était LPSOLTXp GDQV SOXVLHXUV IRQFWLRQV SK\VLRORJLTXHV WHO TXH O¶pYHLO OH
métabolisme énergétique, la motivation, le stress et les comportements liés aux phénomènes de 
récompense. Le système hypocrétinergique est composé G¶HQYLURQ 3000-4000 neurones issus de 
O¶K\SRWKDODPXV ODWpUDO SURMHWDQW dans tout le cerveau. Des souris transgéniques pour le gène des 
hypocrétines ont été générées et leur phénotype correspond à celui des animaux sauvages, excepté le fait 
TX¶HOOHV VRient atteintes G¶DWWDques de sommeil similaires à celles observées chez les patients 
narcoleptiques. Il semblerait que les hypocrétines soient requises SRXU O¶DFTXLVLWLRQ HW O¶H[SUHVVLRQGH la 
dépendance aux drogues. Cependant, le mécanisme précis reste encore à être élucidé. Dans ce rapport, nous 
rendons compte des comportements liés aux phénomènes de récompense liés jO¶DOFRROHWjODcocaïne chez 
les souris knock-out (KO), hétérozygotes (HET) et sauvages (WT).  
Nous avons, dans un premier temps, pYDOXpO¶LPSDFW d¶injections répétées de cocaïne (15 mg/kg, ip) sur la 
sensibilisation locomotrice et sur le conditionnement place préférence. Nous avons pu observer que les 
souris WT, HET et KO exprimaient une sensibilisation locomotrice induite par une administration 
chronique de cocaïne, cependant les souris déficientes en hypocrétines démontraient une sensibilisation 
retardée et atténuée. Il est intéressant de mentionner que les mâles HET exprimaient une sensibilisation 
comportementale intermédiaire. Après normalisation des données, toutes les souris exprimaient une 
amplitude de sensibilisation similaire, excepté les souris mâles KO qui affichaient, le premier jour de 
traitement, une sensibilisation locomotrice réduite et retardée, reflétant un phénotype hypoactif plutôt 
TX¶une altération de la réponse aux traitements chroniques de cocaïne. Contre toute attente, toutes les souris 
femelles exprimaient un pattern similaire de sensibilisation locomotrice à la cocaïne. Nous avons ensuite 
pYDOXpO¶HIIHWG¶XQ conditionnement comportemental à un environnement associé à des injections répétées 
de cocaïne (15 mg / kg ip). Toutes les souris, quelque soit leur sexe ou leur génotype, ont manifesté une 
préférence marquée pour l'environnement apparié à la cocaïne. Après deux semaines d'abstinence à la 
cocaïne, les mâles et les femelles déficientes en hypocrétines Q¶H[SULPDLHQWSOXVDXFXQHSUpIpUHQFHSRXUOH
compartiment précédemment associé à la cocaïne. Alors que les souris WT et HET maintenaient leur 
préférence pour le compartiment associé à la cocaïne. Pour finir, jO¶DLGHG¶XQQRXYHDXSDUDGLJPHDSSHOp
IntelliCage®, nous avons pu évaluer la consommation de liquide chez les femelles WT, HET et KO. 
/RUVTX¶LOQ¶\DYDLWTXHGH O¶HDX disponible, nous avons observé que les femelles KO avaient tendance à 
moins explorer les quatre coins de la cage. Lorsque les souris étaient exposées à quatre types de solutions 
différentes (eau, 1mM quinine ou 0.2% saccharine, alcool 8% et alcool 16%), les souris KO avaient 
tendance à moins consommer O¶eau sucrée et les solutions alcoolisées. Cependant, après normalisation des 
données, aucune différence significative n'a pu être observée entre les différents génotypes, suggérant que 
la FRQVRPPDWLRQUpGXLWHG¶HDXVXFUpHRXG¶alcool peut être incombée jO¶K\SRDFWLYLWp des souris KO. 
Ces résultats confirment que le comportement observé chez les souris KO serait dû à des compensations 
développementales, puisque la sensibilisation locomotrice et le conditionnement comportemental à la 
cocaïne étaient similaires aux souris HET et WT. En ce qui concerne la consommation de liquide, les souris 
KO avaient tendance à consommer moins G¶HDX sucrée et de solutions alcoolisées. Le phénotype hypoactif 
des souris déficientes en hypocrétine est probablement responsable de leur tendance à moins explorer leur 
environnement. IOUHVWHHQFRUHjGpWHUPLQHUVLO¶H[SUHVVLRQGHFe phénotype est la conséquence G¶XQpWDWGH 
vigilance amoindri ou G¶XQH motivation diminuée à la recherche de récompense. Nos résultats suggèrent 
que les souris déficientes en hypocrétine affichent une motivation certaine à la recherche de récompense 
ORUVTX¶HOOHV VRQW H[SRVpHV j GHV environnements où peu d'efforts sont à fournir afin G¶obtenir une 
récompense. 
Abstract 
Drug addiction is a multifactorial disorder affecting human beings regardless their education level, their 
economic status, their origin or even their gender, but the vulnerability to develop addiction depends on 
environmental, genetic and psychosocial dispositions. Drug addiction is defined as a chronic relapsing 
disorder characterized by compulsive drug seeking, with loss of control over drug intake and persistent 
maladaptive decision making in spite of adverse consequences. The brain mechanisms responsible for drug 
abuse remain partially unknown despite accumulating evidence delineating molecular and cellular 
adaptations within the glutamatergic and the dopaminergic systems. However, these adaptations do not 
fully explain the complex brain disease of drug addiction. The identification of other neurobiological 
factors responsible for the vulnerability to substance abuse is crucial for the development of promising 
therapeutic treatments able to alleviate signs of drug dependence.  
For the past few years, growing evidence demonstrated that a recently discovered brain circuit, the 
hypocretinergic system, is implicated in many physiological functions, including arousal, energy 
metabolism, motivation, stress and reward-related behaviors. The hypocretin system is composed of a few 
thousands neurons arising from the lateral hypothalamus and projecting to the entire brain. Hypocretin-
deficient mice have been generated, and unexpectedly, their phenotype resembles that of wild type mice 
excepting sleep attacks strikingly similar to those of human narcolepsy patients. Evidence suggesting that 
hypocretins are required for the acquisition and the expression of drug addiction has also been reported; 
however the precise mechanism by which hypocretins modulate drug seeking behaviors remains a matter of 
debate. Here, we report alcohol and cocaine reward-related behaviors in hypocretin-deficient mice (KO), as 
well as heterozygous (HET) and wild type (WT) littermates. 
We first evaluated the impact of repeated cocaine injections (15 mg/kg, ip) on locomotor sensitization and 
conditioned place preference. We observed that WT, HET and KO mice exhibited behavioral sensitization 
following repeated cocaine administrations, but hypocretin deficient males displayed a delayed and 
attenuated response to chronic cocaine administrations. Interestingly, HET males exhibited an intermediate 
pattern of behavioral sensitization. However, after standardization of the post-injection data versus the 
period of habituation prior to cocaine injections, all mice displayed similar amplitudes of behavioral 
sensitization, except a reduced response in KO males on the first day, suggesting that the delayed and 
reduced cocaine-induced locomotor sensitization may reflect a hypoactive phenotype and probably not an 
altered response to repeated cocaine administrations. Unexpectedly, all female mice exhibited similar 
patterns of cocaine-induced behavioral sensitization. We then assessed the behavioral conditioning for an 
environment repeatedly paired with cocaine injections (15 mg/kg ip). All mice, whatever their gender or 
genotype, exhibited a robust preference for the environment previously paired with cocaine 
administrations. Noteworthy, following two weeks of cocaine abstinence, hypocretin-deficient males and 
females no longer exhibited any preference for the compartment previously paired with cocaine rewards 
whereas both WT and HET mice continued manifesting a robust preference. We finally assessed drinking 
behaviors in WT, HET and KO female mice using a novel paradigm, the IntelliCages®. We report here that 
KO females tended to less explore the four cage corners where water was easily available. When exposed 
to four different kinds of liquid solutions (water, 1mM quinine or saccharine 0.2%, alcohol 8% and alcohol 
16%), KO mice tended to less consume the sweet and the alcoholic beverages. However, after data 
standardization, no significant differences were noticed between genotypes suggesting that the hypoactive 
phenotype is most likely accountable for the trend regarding the reduced sweet or alcohol intake in KO. 
Taken together, the present findings confirm that the behavior seen in Hcrt KO mice likely reflects 
developmental compensations since only a slightly altered cocaine-induced behavioral sensitization and a 
normal behavioral conditioning with cocaine were observed in these mice compared to HET and WT 
littermates. With regards to drinking behaviors, KO mice barely displayed any behavioral changes but a 
trend for reducing sweet and alcoholic beverages. Overall, the most striking observation is the constant 
hypoactive phenotype seen in the hypocretin-deficient mice that most likely is accountable for their 
reduced tendency to explore the environment. Whether this hypoactive phenotype is due to a reduced 
alertness or reduced motivation for reward seeking remains debatable, but our findings suggest that the 
hypocretin-deficient mice barely display any altered motivation for reward seeking in environments where 
low efforts are required to access to a reward. 
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1 Introduction
1.1 Addiction
1.1.1 General introduction
From the early stage of mankind, human beings learned to use plants for their nutritive, thera-
peutic, and psychotropic properties. Evidence found 3000 years BC shows that Mesopotamian
could precisely describe numbers of disease (conjunctivitis, urinary problems, gynecologic disor-
ders, venereal diseases or pulmonary troubles) and treat them with plants. For example, cypress,
oleander, thyme and willow leaves were known for their anti-inflammatory and analgesic action.
Further evidence shows that the psychoactive effects of hemp or poppy were also experienced.
These plants that are still used nowadays were already found illustrated on the Mesopotamian
palace. At that time, Mesopotamian physicians used their sedative and analgesic properties to
perform minor surgeries. Evidence also depicted hemp and poppy cultivations in China around
2700 years BC. Chewing coca leaves has also been reported for alleviating signs of fatigue and
altitude sickness in Equator and in Peru around 2500 years BC.
For centuries, geographic migrations have allowed a large widespread of psychotropic plants
and their cultivations have been extended to regions poor in psychoactive plants. Progresses in
chemistry and medicine allowed to describe, isolate and even synthesize number of psychotropic
compounds during the 19th century. These major advances did drastically change the pattern of
cultivation, distribution and consumption of these plants leading to social problems and public
health concerns. During the 19th century, coca leaves extract (cocaine) reached Europe and
was largely exploited for its medical use before becoming a must-have product that was widely
commercialized. Cocaine was found on domestic markets in various forms such as cigarette,
powder, beverage and soluble preparation for injection. During the 20th century, cocaine use
became a public health concern, but was not prosecuted until the seventies when it became a
controlled substance. Nowadays, drugs of abuse are still a major public health concern with
important economic issues, including preventions, repressions and treatments. Even if drugs of
abuse are considered harmful, they remain easy to access and difficult to combat, as they widely
circulate at moderate prices. In addition, newer synthetic drugs of abuse with high potential for
addiction have been developed (for example, ecstasy, LSD and methamphetamine).
In summary, chemistry has made major progresses allowing the extraction and synthesis of
the main psychoactive compounds found in psychotropic plants. Drug design also allowed the
emergence of synthetic drugs with high potential for abuse. Hence, these new therapeutical
approaches opened a promising window of opportunity but also raised a serious threat on public
health.
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1.1.2 The neurobiology of drug addiction
Drug abuse is a chronic relapsing disorder defined as a progressive neglect of alternative sources
of reinforcement concomitant with the development of compulsive substance taking that persists
despite evidence of harmful consequences. The inability to control substance taking is thought
to be a complex disease process of the brain that results from recurring drug intoxication. It is
also considered as a multifactorial psychiatric disease depending on environmental, genetic and
psychosocial dispositions.
Addictive drugs act directly in the brain, specifically in the limbic system, where they over-
stimulate brain structures and induce molecular and cellular adaptations. These modifications
are complex and involve drug-induced changes in gene transcription, membrane excitability
and neuronal morphology leading to important behavioral consequences. Addiction is not trig-
gered instantaneously upon exposure to drugs of abuse. It involves multiple, complex neural
adaptations that develop over time ranging from hours to days and months. A key feature
of the neurobiological research on drug addiction is a better comprehension of the molecular,
pharmacological and circuitry changes underpinning biased decision making processes, and the
overwhelming desire for the drug (craving) associated with the high risk of relapse to drug seek-
ing after a period of abstinence.
Drugs of abuse often induce brain adaptations leading to sensitization, tolerance and affec-
tive/physical dependence. For the last 30 years, a growing body of evidence has converged to
the identification of the mesocorticolimbic system as a critical neuronal network responsible for
the addictive disorders.
1.1.3 The anatomy of the mesolimbic dopamine system
The ventral tegmental area (VTA) contains cell bodies of dopaminergic neurons projecting to
the nucleus accumbens (NAcc), amygdala, hippocampus and prefrontal cortex (PFC). Defined
as the mesocorticolimbic dopamine system [1], these neurons are critically implicated in brain
mechanisms of reward, reinforcement and emotional arousal [2]. Their activity has been closely
correlated to the availability of primary rewards such as food, water and sexual behavior [3].
Activation of the mesocorticolimbic dopamine pathway has been argued to represent a neuronal
substrate for the rewarding or reinforcing properties of drugs of abuse [4–9]. As such, drugs of
abuse can produce powerful interoceptive effects that cause them to act as primary reinforcers.
Moreover, repeated exposure to drugs of abuse can produce behavioral and neurochemical sen-
sitization, with subsequent drug exposures producing augmented behavioral responses [10–13].
The ability of the drug, and ultimately of related stimuli, to elicit behavior may be augmented
with repeated administrations or intake of the drug. This phenomenon may depend on sensiti-
zation of dopamine release and resulting neuroadaptations within the NAcc produced by chronic
drug intake [14–16]. However, recent data suggest that this ”mesolimbic dopamine hypothesis”
of drug abuse is only one factor of the neural circuit mediating the effects of illicit drugs on
behavior [17].
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1.1.4 The neurobiological hypotheses related to the transition from controlled
to compulsive drug-seeking
Everitt and Wolf [18] argued that drugs of abuse significantly strengthen the learning involved in
classical and operant conditioning. Therefore, the learned habit of performing a certain behavior
in order to receive drug reinforcement is abnormally strong, and can be understood in terms of
the aberrant engagement of Pavlovian and instrumental learning processes [18,19]. This view is
consistent with the role of midbrain DA neurons in functions more complicated than simple ”re-
ward”. Midbrain DA neurons respond to unpredicted rewards and with training, this response
transfers to stimuli predictive of rewards [20–22]. By signaling reward prediction errors, DA may
act as a teaching signal for striatal learning [20]. Midbrain DA neurons innervate the striatal,
cortical, and limbic regions implicated in addiction, so drug effects on DA neuronal activity may
be important for synaptic ”learning” throughout limbic-cortical circuitry [23].
In contrast, Markou and Koob [24] suggested that activity in brain reward circuitry desensi-
tize as a result of chronic drug use. Koob and Le Moal [15,16] proposed that the transition from
controlled to compulsive drug use involves spiraling down of an ”addiction cycle” that includes
three components: preoccupation/anticipation, binge/intoxication, and withdrawal negative af-
fect. Initial sensitization to the drug’s effects may facilitate the preoccupation/anticipation stage.
However, with increased access to drug, self-administration turns to binge use, and the with-
drawal/negative affect stage appears as opponent processes work to return the internal milieu
to normal. The individual takes even more drug, and withdrawal symptoms become stronger,
which in turn cause the preoccupation for the drug to become even stronger. This spiral through
the cycle of drug administration and addiction continues until homeostatic mechanisms are not
sufficient to oppose the continuous effects of drug administration. At this point, allostatic mech-
anisms are activated such that basal reward function or sensitivity is shifted downward, which
means that more drugs is needed to produce euphoria than when the drug was used for the first
time. The result of this cycle is that the need for the drug, and the loss of control over drug
consumption, is ever growing.
In contrast to hedonic/withdrawal views of addiction, Robinson and Berridge [10, 25, 26]
suggested that the transition to addiction is due to the incentive-motivational consequences of
drug-induced alterations in NAcc-related circuitry that mediate incentive salience. The drug
and the cues associated with it acquire heightened/sensitized incentive value and become ever
more salient to the drug user. Through this process, drugs of abuse gain disproportionate con-
trol over behavior. They hypothesize that it is specifically sensitization of incentive salience of
representations of drug cues and drug-taking that causes the compulsive pursuit of drugs and
persisting vulnerability to relapse in addiction.
Finally, Jentsch and Taylor [27,28] have proposed that impulsivity, resulting from frontostri-
atal dysfunction, plays an important role in addiction, and acts synergistically with sensitization
to produce compulsive drug-seeking behavior. Because it is believed that striato-cortical circuits
are important in the inhibition of common responses in contexts in which they are not relevant,
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the dysfunction of the striato-thalamo-orbitofrontal circuit secondary to chronic use could par-
ticipate in the inappropriately intense motivation to procure and self-administer the drug in
addicted subjects. According to this hypothesis, recent evidence indicates that repeated drug
exposure alters cortical cognitive function and leads to loss of inhibitory control mechanisms.
Monkeys treated repeatedly with cocaine exhibit a specific perseverative pattern of respond-
ing, selecting irrelevant information in the face of new reinforcement contingencies [29]. More
recently, Vanderschuren and Everitt confirmed that drug-seeking becomes compulsive after pro-
longed cocaine self-administration in rats [30].
Akin to this latter hypothesis, over the last decade, Volkow and colleagues have collected
data based on imaging studies of substance abusers and concluded that addiction might be a
disease of compulsion that involves the orbitofrontal cortex (OFC) [31–33].
Perhaps the most striking evidence that confirms a key role played by the OFC in addiction
is the observation that cocaine self-administration in mice lacking the DA transporter (i.e. the
main molecular target of cocaine) results in c-fos activation of the anterior olfactory nuclei
and the piriform cortex, and to a lesser extent the orbital cortex, without inducing any c-fos
activation of the NAcc (considered a target of the reinforcing effects of cocaine) [34].
1.1.5 The glutamate and dopamine systems
Drugs of abuse induce long term molecular and morphological modifications following acute
and chronic administration which occur in both the dopaminergic and the glutamatergic sys-
tem. The dopamine neurotransmitter is critical for the neural adaptations which underlie the
generation of behavioral responses to relevant events [35]. On the other hand, glutamate home-
ostasis also affects synaptic activity and plasticity by controlling extracellular glutamate levels
in the synaptic and perisynaptic extracellular environment [36]. Drugs of abuse cause long term
changes on behavior by altering neuronal function and plasticity in brain circuits [36]. Long
term potentiation (LTP) and long term depression (LTD) are important plasticity mechanisms
associated to learning and memory. LTP and LTD are important candidate mechanisms for the
drug induced responses during the development of addiction [37, 38]. Both LTP and LTD are
mediated by AMPARs and N-methyl-D-aspartate receptors (NMDARs) [37, 38]. Interactions
between addictive drugs and synaptic plasticity in different brain regions contribute to specific
aspects of the addiction cycle, such as drug seeking and taking, craving, withdrawal and re-
lapse. Three classical procedures, the behavioral sensitization, the conditioned place preference
and the self-administration, have been widely used to assess the impact of drugs of abuse on
synaptic plasticity. Behavioral sensitization is commonly assayed as multiple addictive drugs
increased locomotor activity which is progressively augmented with repeated administrations
which is characteristic of neuronal adaptations. Conditioned place preference assesses the re-
warding effects of drugs of abuse intoxication by evaluating the potency of addictive drugs to
trigger drug seeking behavior. And self-administration is an operant procedure which promotes
drug seeking/drug taking, withdrawal and relapse behaviors and evaluates the sustained neu-
ronal adaptations over months.
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Following the first cocaine exposure, dopamine neurons undergo synaptic plasticity. A sin-
gle exposure to cocaine induces potentiation of the glutamatergic system through AMPARs
and NMDARs which lasts for 5 days in dopamine neurons [39]. Chronic substances of abuse
treatments maintain similar potentiation relative to the first drug exposure which consolidate
neuronal modifications. The glutamatergic system is implicated in many behavioral outcomes
since NMDARs transgenic mice model or blockade of the NMDARs specifically in the VTA
prevents behavioral sensitization, conditioned place preference and self-administration [40–42].
In addition, the dopaminergic system showed neuronal adaptation following addictive drugs
exposures. Dopamine receptor redistribution has been observed in mesolimbic structures, es-
pecially in the NAcc, the PFC and in the VTA. All these regions express DA receptor 1 (D1)
and receptor 2 (D2). It seems that D1 is induced by phasic firing which privileges long term
potentiation (LTP) and D2 is induced by tonic, basal, firing which facilitates long term depres-
sion (LTD) like state. Chronic cocaine also causes long term changes in both the NAcc and the
PFC. For example, in the striatum, dopamine receptors D2 are downregulated following chronic
exposure to cocaine [43]. Imaging experiments in primates and human brains demonstrate that
psychostimulant abusers showed low levels of D2 receptor [44–46]. DA phasic firing modulates
many behavioral responses [47]. By inducing phasic firing with the help of optogenetic tools in
dopaminergic neurons, Tsai et al. [48] were able to induce conditioned place preference in mice.
In addition, blockade of dopamine receptors or the use of knock out transgenic mice support the
hypothesis that dopamine is implicated in behavioral sensitization, conditioned place preference
and self administration [49,50].
Since cocaine and alcohol treatments affect brain circuits activation and behavior reflecting
modifications at the cellular level, large range of studies focused on molecular changes consid-
ering gene transcription, protein expression or posttranslational modifications. For example,
following chronic exposure, two transcription factors, ∆FosB and CREB, accumulates in the
NAcc cells [51]. Both proteins are transcriptional activators which enhance transcription sig-
naling promoting the expression of numbers of gene such as growth factor, hormones, etc which
modulate synaptic plasticity, growth and survival. Since both have important role in many pro-
cesses such as neuronal growth, it is not surprising that both induce long lasting morphological
modifications in addictive brain, including reduction in the size of cell bodies and in neurofil-
ament amounts, as well as spine density [51]. These evidence suggest that both transcription
factors might be responsible for morphological adaptation which could be reflected through the
abnormal brain activities observed by imaging approaches in addicted individuals [52].
Understanding the basic neurobiological processes sustained by natural and pharmacological
reward will promote a better knowledge for drug of abuse-induced machinery and thus for treat-
ments. For more than twenty years, reward processing was mainly focused on two specific neu-
rocircuits, the glutamatergic and dopaminergic systems, which partially explain how substances
of abuse hijack natural reward circuitry ranging from molecular mechanisms to behavioral out-
comes. Recently, a new system was discovered, the hypocretin system, which demonstrated
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implication in many behavioral states and interestingly in reward processing.
1.2 The hypocretin system
More than 10 years ago, two different groups have discovered independently a new family of
neuropeptides, the hypocretins, also known as orexins. Since then, a growing number of evi-
dence has implicated the hypocretins in a variety of physiological processes, such as arousal,
metabolism, reward, sleep and stress.
Early observations came from Gautvik et al. [53]. The group focused on establishing a
database composed of all mRNAs that are only expressed in the hypothalamus; this structure
has an important role for maintaining basal body homeostasis and especially feeding behaviors.
This open system search allowed highlighting 22 novel mRNAs highly enriched in the hypotha-
lamus. In situ hybridization on coronal sections was performed using all clones including the
clone of the hypocretin peptides and revealed that hypocretins were restricted to a few neurons
distributed bilaterally in the lateral hypothalamic area [54]. In the meantime, the group of M.
Yanagisawa was searching for potential ligands of orphan G-protein coupled receptors (GPCRs);
these receptors are main pharmacological targets by inhibiting upstream pathways. A systemic
biochemical approach was performed to screen endogenous peptide ligands for multiple orphan
GPCRs leading to the identification of two peptides which they named orexins. Autoradiogra-
phy of in situ hybridization on coronal sections showed that the orexins neurons were located
in the lateral part of the hypothalamus (LH) [55]. Interestingly, both groups observed a similar
pattern of expression; the localization of both peptides was restricted to the dorsal and lateral
part of the hypothalamus, in particular in the perifornical region (PeF) and the dorsomedial hy-
pothalamic nucleus (DMH), indicating that both peptides were identical [54,55]. In the current
report, the term hypocretin will be used.
The hypocretin family is composed of a precursor, the preprohypocretin (ppHcrt), which
after post-translational processing is cleaved into two neuropeptides, hypocretin-1 (Hcrt 1) and
hypocretin-2 (Hcrt 2), also known as orexin-A (Ox-A) and orexin-B (Ox-B) respectively. The
human and rat gene sequences are composed of two exons with an intervening intron which
encodes a 130-residue mRNA. In both species, the prepropeptide is composed of three parts, a
secretory signal sequence of 33 amino acids followed by hypocretin-1 and hypocretin-2 sequences.
Maturation of the prepropeptide starts with the removal of the signal sequence followed by pro-
teolytic cleavages which give birth to two neuropeptides Hcrt-1 composed of 33 amino acids
of 3,562 Da, and Hcrt-2, a 28 amino acids peptide of 2,937 Da (figure 1.1) [55, 56]. To our
knowledge, no alternative splicing variants of the prepropeptide hypocretin were reported either
in human or in rodents. Bioinformatic investigations based on amino acids sequences showed
that hypocretins are homologous and highly conserved throughout species suggesting important
physiological roles [57, 58].
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Figure 1.1: Hypocretin peptides. Maturation of preprohypocretin in hypocretin-1 and hypocretin-2.
Hypocretins expression takes place early in the development and is age-dependent. Rodent
preprohypocretin mRNA is found at low concentration at embryonic day 18 (E 18) and is weakly
detected at birth (PD 0) [54,59]. From PD 0 to PD 15, mRNA levels increase gradually and are
strongly enhanced between PD 15 and 20 until reaching a plateau at 3 weeks of age which are
maintained during adulthood [54, 59, 60]. Hypocretins expressions are stable from 3 weeks to
12-month of age and begin to decline after 12 months and keep decreasing with aging [61–63];
between PD 400 and PD 800, hypocretin neurons decrease of 15% and of 29% between PD 800
and PD 1000 [62]. In the present report, all animals used were tested during adulthood.
Hypocretin neurons are found in many brain regions (see figure 1.2) and application of
hypocretin peptides promotes neuronal activity through two G-protein coupled receptors (GPCRs),
hypocretin receptor 1 (HcrtR1) and hypocretin receptor 2 (HcrtR2), also known as orexin 1
receptor (OX1R) and orexin 2 receptor (OX2R) respectively [55]. The hypocretin-1 peptide
binds to both HcrtR1 and HcrtR2 with a high affinity, whereas hypocretin-2 binds selectively
to HcrtR2 with a similar high affinity [55]. Similar to Hcrt-1 and Hcrt-2 peptides, HcrtR1 and
HcrtR2 are highly conserved throughout species; hypocretin receptors were detected in human,
rodent, pig, bovine and fish. The genomic sequence of the mouse HcrtR1 consists of nine ex-
ons spanning on 9kb and the mouse HcrtR2 consists of eight exons of more than 40kb [64].
G protein coupled receptors have characterized conformation structure; they are composed of
a N terminal extracellular domain followed by 7 transmembrane domains linked by intracel-
lular and extracellular loops and ended by a C terminus intracellular domain which mediates
downstream molecular pathway through G-proteins, including Gs, Gq and Gi/o subtypes [65–67].
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Figure 1.2: Hypocretin neurons projection. Schematic drawing of the hypocretin system on a sagittal section through
the rat brain. Illustration depicts the principal structures receiving dense innervation of hypocretin neurons where dots
represents hypocretin cell bodies. Amyg.: amygdala; BNST: bed nucleus of stria treminalis; CP: caudate putamen;
LC: locus coeruleus; NAcc: nucleus accumbens; VTA: ventral tegmental area.
Establishment of the anatomical expression pattern of the neuropeptides (see figure 1.2) and
receptors (figure 1.3) gives indications on the physiological roles of hypocretins. Interestingly,
the hypocretin system which is composed of a few thousand neurons projects throughout the
brain. Hypocretin fibers and hypocretin receptor expression patterns are consistent. However,
differential HcrtR1 and HcrtR2 distributions were found; HcrtR1 and HcrtR2 expression pattern
are complementary in many cases, but overlapping distributions can also be observed in certain
brain regions [68–72] (figure 1.3).
Hypocretin neurons and receptors were found within the tuberomammillary nucleus (TMN),
the locus coeruleus (LC), the dorsal raphe (DR) and the laterodorsal tegmental area / peduncu-
lopontine tegmental nucleus (LDT/PPT), as well as the ventrolateral preoptic nucleus (VLPO);
these structures are involved in arousal and sleep regulation. They were also found in the PFC,
the amygdala, the BNST, the hippocampus, the paraventricular hypothalamic nucleus (PVN)
and the VTA. Hypocretin fibers and receptors were also observed in motor related subcircuit,
the caudate putamen (CP) and the substantia nigra. They could be found in autonomic centers,
the periaqueductal gray matter, the nucleus of the solitary tract (NTS) and the parabriachal
nucleus and the septum. [68–78]. Evidence showed hypocretin neurons and receptors in the
olfactory bulb [79] and the cerebral cortex. In turn, hypocretin neurons receive afferences from
many of these brain regions [78, 80].
Hypocretin peptides and receptors were also observed in the peripheral tissues of both hu-
man and rat, including the lung, the myenteric plexus of the enteric nervous system [81] the
endocrine cells of the gut [81, 82], the pancreas [82, 83], the adrenal gland [84–86], adipose tis-
sues [87], epidermis and testis [84, 88, 89].
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Figure 1.3: Hypocretin receptors distribution. Schematic drawing of the hypocretin receptors distribution on a sagittal
section through the rat brain. It illustrates the principal structures where hypocretin receptors were observed. HcrtR1 is
shown in red, HcrtR2 in blue and HcrtR1 and HcrtR2 overlapping expression is illustrated in yellow. Amyg.: amygdala;
BNST: bed nucleus of stria treminalis; CP: caudate putamen; LC: locus coeruleus; NAcc: nucleus accumbens; TMN:
tuberomammillary nucleus; VTA: ventral tegmental area.
The anatomical profile of the hypocretin system suggests that it mainly targets monoamin-
ergic circuits, including cholinergic, dopaminergic, noradrenergic and serotoninergic systems
[73–75]. These systems are responsible for homeostatic regulations and behavioral outputs.
Hypocretin neuronal population could be divided in two fields regarding afferent projections,
suggesting a specialization of those neurons in mediating specific responses in respect of the stim-
uli involved [78]. The medial part seems to be linked to waking and stress and the lateral part
seems to be connected with structures that are implicated in reward related behaviors [90–92].
However, this hypothesis is not supported by many authors. Nevertheless, it seems that the
hypocretin system is able to sense and integrate environmental stimuli and, because of its key
position in the brain, induces the activation of the different centers mediating arousal, emo-
tion, energy metabolism, reward, sleep and stress. In order to better understand the functional
roles of hypocretins, transgenic animals (constitutive ppHcrt KO mice or the hypocretin/ataxin3
mice), agonists (synthetic Hcrt-1 or Hcrt-2) or antagonists have been developed. The first phar-
macological hypocretin antagonist, SB-334867 which is still widely used, significantly inhibits
HcrtR1 mediated response in a concentration-dependent manner [93]. SB-334867 can penetrate
the blood brain barrier, in spite of its low bioavailability [94], and following intraperitoneal ad-
ministration of 30 mg/kg maintains good exposure over 4h [95]. However, SB-334867 did also
show some affinity for 5-HT2B and 5-HT2C receptors and other GPCRs [94].
1.3 The physiological roles of the hypocretin system
1.3.1 Arousal and sleep
Arousal and sleep are regulated through the activity of suprachiasmatic nucleus (SCN) and of
monoaminergic neurons in the TMN, the LC, the DR, the VTA, and the LDT/PPT, as well as
the VLPO [96]. The SCN is thought to orchestrate the circadian clock and its main target is
the dorsomedial part of the hypothalamus, which hosts in its vicinity the hypocretin-producing
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neurons [97–99]. Moreover anatomical evidence showed that the SCN innervated the medial part
of hypocretin-containing cells field [78]. Interestingly, hypocretins levels vary according to the
circadian cycle with high levels of peptides during the wake-active period and low levels during
the sleep period [100, 101]. Lesioning the SCN disrupts Hcrt circadian rhythm [102]. The DR,
the LC, and the TMN , defined as the wake-active centers, are activated by the SCN and interact
with the hypocretin system. In vitro electrophysiological observations showed that all these re-
gions changed their firing rate after hypocretin application [103–108], except the VLPO [109] and
intracerebroventricular (icv) administration of hypocretins in the structures mentioned above
during the light period has been reported to increase arousal and decreased REM and non-
rapid eye movement (NREM) sleep time [103, 110–112]. In contrast, pharmacological blockade
of both hypocretin receptors, HcrtR1 and HcrtR2, promotes sleep [113]. Thus, during the wake-
active period, activation of hypocretin neurons by the SCN results in the depolarization of the
waking promoting centers. Hypocretins may mediate activation of the LC/noradrenaline sys-
tem through HcrtR1 [114, 115], the TMN/histaminergic system through HcrtR2 [108, 116] and
the DR/serotoninergic system through both HcrtR1 and HcrtR2 [107]. These monoaminergic
systems subsequently inhibit the VLPO and the hypocretin neurons. In addition, hypocretins
neurons promote arousal through the activation of HcrtR2 in the LDT/PPT [106, 117–119].
These evidence strongly suggest that hypocretins are mainly driving wakefulness. On the other
hand, during the sleep-active phase, the activity of SCN and hypocretin neurons decreases which
indirectly abolishes the inhibition of the VLPO [120]. The VLPO appears to play a critical role
in the initiation of NREM sleep and maintenance of both NREM and REM sleep. The VLPO
sends inhibitory projections to the arousal centers and the hypocretin neurons, therefore pro-
moting sleep. These evidence indicate that the hypocretin system mainly drives arousal state
and when it is impaired, altered sleep/wake pattern is observed.
Hypocretins are implicated in narcolepsy, a neurological disorder defined as excessive day-
time sleepiness associated with unstable boundaries between sleep and wakefulness. In other
word, narcolepsy is characterized by a sudden recurrent uncontrollable compulsion to sleep
(sleep attacks). These sleep attacks can last from a few seconds to more than an hour. Nar-
colepsy is often associated with cataplexy, which is characterized by a sudden loss of muscle
tone and sleep paralysis. Narcolepsy is tightly associated with genetic dispositions and espe-
cially related with the HLA system. Further, progressive loss of hypocretin neurons has been
shown to trigger the disease [121–124]. Narcolepsy patients with cataplexy carry the HLA
haplotype DRB5*0101-DRB1*1501-DQA1*0102-DQB1*0602 allele [125] and have reduced or
undetectable hypocretin levels in their cerebrospinal fluid. It is speculated that an autoimmune
process kills the Hcrt-producing neurons. Recently, the identification of circulating Tribbles
2 (Trib2)-specific antibodies, known to be involved in multiple autoimmune disorders, gives
new insight of the mechanisms involved in the development of narcolepsy. Trib2-specific an-
tibody titers were higher in the narcoleptic patients than that of controls and Trib2-specific
antibodies showed specific immunoreactivity with hypocretin neurons in the mouse hypothala-
mus, providing the first evidence that narcolepsy is an autoimmune disorder [126]. Interestingly,
narcoleptic patients almost never carried a DRB1*1301-DQB1*0603 haplotype, suggesting a
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protective allele against other HLA associated disorders [127]. In addition, mutation of the
HcrtR2 also caused narcolepsy in humans and in agreement with this observation, narcoleptic
dogs have disrupted HcrtR2 gene [128]. The generation of transgenic mice confirmed the impli-
cation of the hypocretin system in narcolepsy. Constitutive preprohypocretin, HcrtR2 or dual
HcrtR1/HcrtR2 knockout mice and hypocretin neuron-ablated mice, also exhibited narcoleptic-
like phenotype [129–133]. These transgenic lines exhibit more transitions from wakefulness to
rapid eye movement (REM) sleep during the dark phase. The sleep and the active cycles are
fragmented and reduced relative to WT recordings [129–133] and rescuing the hypocretin sys-
tem with hypocretin gene transfer or administration of synthetic hypocretin restore the normal
sleep/wake pattern [132]. Using optogenetic tool, Adamantidis et al. [134] promoted wakefulness
by photostimulating the LH. LH photostimulation promoted rapid awakening in WT animals
than that of ppHcrt KO mice. Interestingly, heterozygous animals issued form the backcross
of constitutive ppHcrt KO mice, did not exhibit any narcoleptic-like phenotype, even though
hypocretin-1 and hypocretin-2 expression levels are reduced mimicking the progressive decrease
of hypocretins levels observed in narcoleptic patients [122–124]; hypocretin levels in HET animals
reach 75% and 83% respectively relative to hypocretin levels in WT animals [55]. On the other
hand, overexpression of the human preprohypocretin gene in mice also altered the sleep/wake
cycles. Transgenic mice overexpressing Hcrt exhibited reduced REM sleep during both light
and dark periods compared to WT [135, 136]. These evidence suggest that the hypocretins are
intimately linked to wake/sleep regulation. This confirms that either the absence or the high
expression of hypocretins induced impairment in arousal/sleep cycles.
Figure 1.4: The hypocretin system: Arousal/Sleep. Schematic drawing of the structure involved in arousal/sleep.
During the wake-active period, activation of hypocretin neurons by the SCN depolarizes the LC, the LDT/PPT, the
raphe, and the TMN. The LC, LDT/PPT, the raphe and the TMN inhibit the VLPO, thus promoting wakefulness.
During the sleep-active phase, the activity of SCN and hypocretin neurons decreases abolishing the inhibition of the
VLPO. The VLPO promotes sleep by inhibiting the LC, LDT/PPT, the raphe, the TMN and the LH.
1.3.2 Attention
Levels of awareness and sleep involve interactions between the thalamus and the cortex. Patients
with impaired sleep-waking cycles exhibit attentional deficits [137]. The executive attention
network of the medial prefrontal cortex permits the sharing of attention among different potential
sources of information [138]. Damage to part of this region is thought to result in concentration
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difficulties [139]. The majority of patients with such thalamic lesions exhibit deficits on tests
assessing fronto-executive functions [140]. Interestingly, narcoleptic patients exhibit attention
difficulties [141]. The Hcrt system is anatomically connected to thalamic nuclei and prefrontal
cortex suggesting a role for Hcrt in attention [78]. Hcrt peptides and receptors are found
in the paraventricular thalamic nucleus (PVT) which in turn projects to the ventral part of
medial prefrontal cortex (mPFC), particularly the infralimbic and prelimbic cortices, nucleus
accumbens, and amygdala [142]. Hypocretins have recently been shown to depolarize thalamic
neurons through the HcrtR2 [142, 143]. Hcrt-1 application stimulates cortical neurons [144].
In addition, Hcrt was shown to excite thalamocortical terminals in the prefrontal cortex [145].
Further evidence established hypocretins may be involved in attention [146]. Nasal delivery
of the synthetic Hcrt-1 peptide reverses the attentional performance deficits produced by sleep
deprivation, whereas pharmacological blockade of HcrtR1 decreased performance [147]. Since
Hcrt fibers have been shown to innervate both the NAcc [148] and the insula [149], it is tempting
to speculate that Hcrt may contribute to define behavioral strategies by optimizing the processing
of environmental signals in attention-demanding tasks with regard to past experience. Hence, the
Hcrt system may enhance cognitive arousal and attentional performance for improving prediction
making, and drive sustained attention for achieving the goal-oriented behavior whatever the
context is: reward seeking or punishment avoidance [150,151].
1.3.3 Feeding behavior
It has been suggested that perturbation of the sleep/wake cycles leads to impaired feeding
behavior [152–154]. In addition, the SCN, which is known to induce circadian rhythm, also
regulates the endocrine system [83, 97]. Large range of hormonal orexinergic peptides, such as
ghrelin and anorexinergic peptides, such as cholecystokinin, insulin and leptin are involved in the
maintenance of the appropriate energy balance regarding the environment and the needs [155].
Most of these circulating endocrine peptides involved in energy metabolism are regulated in
function of the circadian cycle and activates the LH. The hypothalamus, especially the medial
and the lateral part, controls appetite; lesions of these specific nuclei lead respectively to obese
and anorexia phenotypes [156]. Further, the LH peptides, hypocretins, are related to the in-
cretin family, especially with secretin [57, 58], but an alternative assumption postulates that
hypocretins may be related to the bombesin family [157]. Nevertheless, both peptide families
are implicated in the regulation of feeding behaviors. Electrophysiological data support the idea
that hypocretin-containing neurons are regulated by anorexinergic and orexinergic mediators.
The application of glucose and leptin have been shown to induce hyperpolarization associated
with decrease in firing rates in a dose dependent manner, while choleocystokinin and ghrelin
depolarize dose-dependently hypocretin neurons and increase the spiking frequency [158, 159].
Icv injection of synthetic Hcrt peptides enhanced food intake [55, 160, 161], whereas treatment
with the pharmacological antagonist SB-334867 reduced food consumption [95]. In contrast, no
difference in food intake was observed, when hypocretins were administered systemically [162].
In transgenic lines, hypocretins seem to promote both energy expenditure and food intake;
constitutive ppHcrt KO or hypocretin/ataxin3 KO mice are hypophagic, but do have normal
body weights compared to WT animals. In addition, hypocretin/ataxin3 KO mice lose less
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weight under fasting conditions and develop obesity over time, while ppHcrt KO tend to be
overweighed [163]. These evidence suggest that hypocretins may contribute to the maintenance
of appropriate energetic stores during the wake active phase.
Orexinergic and anorexinergic peptides activates the LH, but also the arcuate nucleus. The
arcuate nucleus plays an integrative role in feeding behaviors by receiving signals from peripheral
tissues. Two populations of neurons are found in the arcuate nucleus, the neuropeptide Y (NPY)
/ agouti gene related peptide (AGRP) producing neurons and the cocaine- and amphetamine-
regulated transcript (CART) / proopiomelanocortin (POMC) containing neurons [155,164]. The
hypocretin neurons are anatomically linked to the arcuate nucleus and contact both NYP/AGRP
and CART/POMC neurons [73,78,165,166]. Stimulation of the NPY/AGRP neurons activates
hypocretin neurons which, in turn, send positive feedback to the latter. Then both NPY/AGRP-
and hypocretin-producing neurons inhibit CART/POMC neurons [167, 168]. Taken together,
these observations suggest that the arcuate and the lateral hypothalamus act synergistically to
stimulate the anabolic pathway and promote feeding behavior during the wake active periods.
Further, NPY/AGRP, CART/POMC and hypocretin neuronal populations also innervate
the paraventricular nucleus of the hypothalamus which, in turn, sends feedback projections to
the arcuate nucleus and the LH. The PVN is a complex structure considered to be an integrator
of the autonomic and neuroendocrine centers. It is composed of different populations of neurons,
namely the magnocellular neurons, the parvocellular neurons, the corticotrophin releasing factor
(CRF) producing neurons, the oxytocin (OXY) containing cells, the thyrotropin releasing hor-
mone (TRH) synthesizing neurons [169, 170]. Interestingly, CRF activation mediates metabolic
stress resulting from negative energy balance and fasting. Direct application of Hcrt-1, but not
Hcrt-2, into the PVN induced food intake behaviors through the activation of the magnocel-
lular, the parvocellular, and the CRF-containing neurons [171–173]. The SCN also projects to
the PVN and the lateral hypothalamus and the activation of both the hypocretin and the CRF
systems synchronize food seeking and food intake with the wake active period [97, 174]. CRF
and hypocretins also mediate many ranges of behavioral stress responses, such as increase in
the locomotor activity. Thus, concomitant activation of the hypocretin and the CRF system
might induce subsequently hyperlocomotion and hyperarousal in order to privilege food seeking
behaviors.
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Figure 1.5: The hypocretin system: feeding behavior. Schematic drawing of the structure involved in feeding
behaviors. The arcuate nucleus, composed of the NPY/AGRP and the CART/POMC neuronal populations, and the
Hcrt neurons of lateral hypothalamus regulate the energy homeostasis. Both nuclei are anatomically and functionally
linked. Hcrt neurons are inhibited by glucose and leptin and activated by cholecystokinin and ghrelin. In the arcuate
nucleus, leptin inhibits the NPY/AGRP neurons and activates the CART/POMC neurons, while ghrelin inhibits the
CART/POMC neurons and activates the NPY/AGRP neurons. Both the arcuate nucleus and the LH integrated signals
to provide coherent feeding behaviors.
1.3.4 Stress
Negative energy balance induces an acute stress response promoting subsequent hyperlocomo-
tion and hyperarousal in order to stimulate food seeking behaviors. Stress is triggered by
emotional, physical or environmental negative affects and is mediated through the activation
of the hypothalamic-pituitary-adrenal (HPA) axis. The activation of the HPA axis stimulates
the release of adrenocorticotropic hormone (ACTH) in the pituitary gland and subsequently
increases the secretion of adrenal cortisol in humans and adrenal corticosterone in rodents. Cor-
tisol and corticosterone are the major downstream mediator of the stress response triggered by
the activation of CRF-producing neurons which are located in the PVN, BNST and the amyg-
dala. CRF activation promotes many ranges of sympathetic tone, including blood pressure,
heart rate, respiratory regulation and behavioral stress responses, such as chewing, gnawing,
grooming, locomotor activity and fighting.
The lateral and the paraventricular nuclei of the hypothalamus are closely connected [78,80]
suggesting that the hypocretin system might be involved in the activation of the brain stress
response pathways. Indeed, application of Hcrt-1 in the HPA axis strongly stimulates CRF-
expressing neurons and in vivo administration of Hcrt-1 increase the circulating corticosterone
levels [172,175–177]. Further, Hcrt administration in rodent enhances grooming and hyperloco-
motion which are considered to be behavioral landmarks of stress related responses [103, 104,
178–181]. Indeed, high levels of hypocretins is correlated to stress prone state in humans and in
rodents [182–184]. By reducing the expression of hypocretins with siRNA or treatment with a
dual antagonist of the hypocretin receptors reduced dose dependently hypocretin levels and the
associated sympathetic responses to stress [184]. Further, in agreement with this observation,
hypocretin deficient mice exhibit reduced stress related response compared to WT [185–187].
However, not all forms of stress are triggered by the hypocretins, exploration or conditioned
fear, but not cold exposure or immobilization, increase the circulating hypocretin levels and
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subsequently the heart rate and the blood pressure [188,189].
Stressful events seem to activate the paraventricular nucleus of the hypothalamus, the lateral
hypothalamus and the amygdala resulting in the release of CRF and Hcrt peptides. Both CRF
and Hcrt may act synergistically to enhance arousal and locomotor activity; CRF and Hcrt
peptides stimulate the NTS, [190–193], which regulates the cardiovascular, gastrointestinal tract
and respiratory systems [194], and activation of the hypocretin pathway leads to the release of
monoamines, notably that of serotonin and noradrenalin promoting the arousal [103, 110–112].
The concomitant action of CRF, Hcrt, noradrenaline and serotonin trigger increased blood
pressure, heart rate, respiratory frequency, muscle tone and hyperarousal. The augmentation of
blood flow gathers all resources to promote energy supply to muscles to initiate motor actions
and hyperarousal trigger the maximum of attention to define the best strategies.
Stressful stimuli could result from diverse sources. For example, drug seeking behavior can
trigger the brain stress pathways. Stress has been reported to contribute to the early neural
adaptations which facilitates the development of drug addiction [195]. A role for the brain stress
pathways has to be taken into account and notably the CRF-producing neurons mediating the
reinstatement of previous reward seeking behaviors.
Figure 1.6: The hypocretin system: Stress. Schematic drawing of the structure involved in stress. Emotional,
physical or environmental negative affects activate the PVN and the amygdala. The activation of CRF-producing
neurons induces the activation of the Hcrt neurons. Release of Hcrt in the PVN promotes the stress response through
the activation of the hypothalamic-pituitary-adrenal (HPA) axis. The activation of the HPA axis stimulates the release
of adrenocorticotropin hormone (ACTH) in the pituitary gland and subsequently increases the secretion of adrenal
cortisol in humans and adrenal corticosterone in rodents.
1.3.5 Reward related behaviors
Addictive drugs can drastically affect brain circuits especially the mesolimbic brain circuitry,
known for evaluating the incentive salience which determines the intensity of behavioral re-
sponding [196]. Interestingly, all mesolimbic structures project to the hypocretin system [78]
and the latter sends reciprocal feedbacks. The VTA is the main source of dopamine which
mediates incentive learning. Interestingly, one of the largest inputs to the VTA dopamine
neurons originates in the lateral hypothalamus and more precisely from hypocretin-containing
neurons [78, 197]. However the VTA is moderately innervated by Hcrt fibers compared to the
LC and the raphe [73–75]. The innervation of the VTA by hypocretin neurons is predominantly
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ispsilateral from the lateral nucleus of the hypothalamus. The VTA mainly sends projections to
the NAcc which mediates the reinforcing effects of drugs of abuse. Hypocretin neurons receive
strong input from the NAcc shell [78]. Moreover, hypocretin neurons do also receive large input
from the amygdala, the BNST, the cerebral cortex and the hippocampus [68,73–75,78].
The hypocretinergic system has not only an anatomical interaction with the dopaminergic
and glutamatergic systems but also functional interactions. Application of hypocretin induces
changes in spiking frequency pattern in many mesolimbic structures [198, 199]. Application of
Hcrt-1 or -2 into the VTA potentiates NMDAR EPSCs in dopamine neurons via both HcrtR2 and
HcrtR1 [200,201]. Hcrt-1 induces late-phase increase in postsynaptic AMPAR-mediated synap-
tic transmission [200]. Hcrt-2 receptor activation could initiate through NMDAR activation or
other mechanisms that facilitate AMPAR trafficking [201]. Direct administration of Hcrt-1 or
Hcrt-2 in the VTA also induces a dose dependent release of DA, with an increased release of
DA after Hcrt-1 application [202]. Not all neurons in the VTA respond to hypocretin peptides;
indeed, application of hypocretin-1 activated preferentially the caudomedial part of the VTA
which in turn projects to the PFC and NAcc shell [203]. Both the PFC and NAcc shell are stim-
ulated by DA release following direct administration of Hcrt in the VTA [180,204]. In addition,
the PFC projects to the NAcc shell. The PFC and the NAcc shell are also potently activated by
hypocretins. In the PFC, hypocretins depolarize cortical neurons [205–207], whereas icv admin-
istration of hypocretins in the NAcc induces hyperpolarization [208,209]. However, hypocretin-2
was more efficient than Hcrt-1 in stimulating both PFC and NAcc through HcrtR2 [142,208,209].
Imaging approach in patients suffering from narcolepsy-cataplexy shows that both the PFC and
NAcc exhibit abnormal brain activation in response to rewarding stimuli compared to healthy
patients [210]. The switch controlled to compulsive drug seeking is mediated by a transition from
goal directed behavior driven by the NAcc to habits formation regulated by the dorsal stria-
tum [211]. It has been reported that the dorsal striatum can also be activated by hypocretins,
since application of hypocretin-1 in striatal neurons upregulates AMPARs, but not NMDARs,
which may mediate a delayed synaptic LTP [212]. The amygdala and the BNST are critical for
establishing learned associations of motivationally relevant events and interact with the NAcc
and the PFC. Amygdala and the BNST are innervated by the hypocretin system and both
Hcrt-1 and Hcrt-2 potently induce depolarization of these structures through HcrtR2 [193,213].
Hypocretin neurons receive in turn large afferents from the amygdala and the BNST [78]. All
dopaminergic and glutamatergic structures involved in reward processing respond electrophysi-
ologically to hypocretins application, especially to the Hcrt-2 peptide, through HcrtR2 which is
consistent with hypocretin neurons and receptors distributions, meaning that hypocretin pep-
tides may be implicated in reward related synaptic plasticity by inducing long term changes in
these structures. Drugs of abuse drastically modify the mesolimbic neurocircuitries by trigger-
ing synaptic plasticity processes and the hypocretin system may contribute to the development
of drug addiction. Interestingly, most of narcoleptic patients treated with amphetamine-like
drug do not abuse their medication [214,215], suggesting that addictive drugs may interact with
hypocretins in order to promote reward related behaviors.
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Figure 1.7: The hypocretin system: Reward related behaviors. Schematic drawing of the structure involved in
reward related behaviors. Positive or negative sensory stimuli induced by drugs of abuse treatment in a specific context
affect the amygdala, the hippocampus and the PFC. All these regions activates the VTA. The VTA mainly sends
projections to the NAcc mediating the reinforcing effects of drugs of abuse and over time engage habits through the
activation of the dorsal striatum. Hypocretin neurons send projections to the VTA, but also to the amygdala and the
PFC. In turn, it receives strong input from the amygdala and the NAcc. The cross communication between the LH
and the mesolimbic structures reinforce the dopamine signaling and promote drug seeking and drug-taking behaviors
which are key features for the development of drug addiction.
Wide range of behavioral procedures are used to dissect drug addiction development and
expression. Here, we present three classical paradigms commonly used: the behavioral sensiti-
zation, the conditioned place preference and the self-administration.
Behavioral sensitization
Multiple different addictive drugs induce hyperlocomotion and behavioral sensitization, defined
as a gradually escalating behavioral and motivational response to a fixed drug dose. The lo-
comotor response induced by daily acute drug administration is progressively enhanced with
repeated administration which generally persists for weeks or months even after cessation of
drug administration, suggesting the involvement of neuronal plasticity processes. However,
when hypocretins are lacking, behavioral sensitization seems to be affected. Indeed, constitutive
ppHcrt KO mice failed to exhibit any robust behavioral sensitization to morphine [204, 216] or
to psychostimulant drugs, including methamphetamine [217], methylphenidate [217] and 3,4-
methylenedioxymethamphetamine (MDMA) [217]. Rodents treated with the HcrtR1 antago-
nist SB-334867 failed to develop normal amphetamine- [218] and cocaine-induced hyperloco-
motion [200]. However, acute blockade of HcrtR1 with SB-334867 does not impair ongoing
behavioral sensitization [200]. These suggest that hypocretins seems to facilitate behavioral
sensitization and therefore drug-induced synaptic plasticity.
Conditioned place preference
The conditioned place preference (CPP) procedure is a form of Pavlovian conditioning in which
distinctive environmental cues become associated with a temporal and motivational event. Place
conditioning is most often used to study the positive motivational effects of drug of abuse acute
intoxication. As a result of this association, the environmental cues are assumed to acquire
the ability to evoke a conditioned motivational response similar to that elicited by addictive
drug administration. Rodents are more likely to approach and spend more time in the context
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associated with positive conditioned stimulus. In such a paradigm, hypocretin neurons seem
to be activated by the evocation of the rewarding effect of the stimulus, as the immediate
early gene c-Fos is express following conditioning for food, cocaine or morphine, but not in
control conditions or novelty [91]. Interestingly, Fos-positive hypocretin neurons were found in
the lateral part of the hypocretin-containing cells field [91]. Pharmacological treatment with the
antagonist of HcrtR1 prior the test session attenuated expression of conditioned place preference
for morphine [219]. Following active extinction, direct administration of hypocretins in the VTA
promotes the reinstatement of the previous extinguished morphine preference [91]. Regarding
constitutive ppHcrt KO mice, conditioned place preference for morphine was attenuated even
following conditioning with high dose of morphine [204]. In addition, WT pretreated with
the HcrtR1 antagonist, SB-334867, displayed a reduced preference for the compartment paired
with repeated morphine injections [204], whereas ppHcrt KO female mice demonstrate similar
preference than WT for the context paired with repeated exposure to 15mg/kg cocaine [216]. It
has been observed that Hcrt may act in the development of associative learning in the conditioned
place preference paradigm, especially in the early phase of conditioning. Excitotoxic lesions in
the LH and/or application of SB-334867 into the VTA impair the expression of CPP for morphine
[219]. Rats trained for CPP show a decrease in hypocretin mRNA expression, especially in
the lateral part of the hypocretin-producing neurons, following repeated pairings between the
context and cocaine [92]. Finally, application of hypocretin-1 and hypocretin-2 in the VTA
potently induces a dose-dependent preference for the drug paired compartment [202]. These
observations suggest that hypocretins are involved in mediating learned association during the
first step of the conditioning phase and potentiate the VTA to the rewarding effect induced
by drugs of abuse or food reward. Interestingly, direct application in the LH of rat pancreatic
polypeptide (rPP), a neuropeptide involved in feeding behavior, activates hypocretin neurons
through Y4 receptors [220] and reinstates extinguished morphine preference [91].
Self-administration
The self-administration paradigm is an operant task, that selectively highlights particular aspects
of the drug experience and the processes contributing to the development of addiction including
acquisition, withdrawal and relapse. Self-administration studies are powerful measures consid-
ered to mimic conditions of addiction whereby the subject is controlling drug delivery. Several
reports explored the role of Hcrt in drug intake with the help of the antagonist of the HcrtR1,
SB-334867. In contrast, only few reports were performed with constitutive or conditional Hcrt
knockout animals.
Hcrt seems to play a role in alcohol consumption and alcohol seeking [221–228]. Admin-
istration of synthetic Hcrt in the LH stimulates alcohol intake [223]. Under fixed ratio (FR)
schedule of reinforcement, blockade of HcrtR1 dose-dependently attenuates responding to al-
cohol [221, 225]. Moreover, SB-334867 potently reduces olfactory cue- and stress-like-induced
reinstatement of alcohol seeking behavior [221,224]. These observations suggest that hypocretin
might be involved in alcohol related behaviors.
Hcrt is also critical for cocaine seeking and taking behaviors. Hcrt-1 dose-dependently re-
instates cocaine seeking behavior [229]. Systemic administration of HcrtR1 antagonist, but
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not HcrtR2 antagonist, attenuates cue-, context- and stress-induced reinstatement for cocaine
[226,229–233]. Similar to behavioral sensitization, blockade of HcrtR1 does not alter the acquired
drug seeking behaviors in rats trained to self-administer cocaine. These evidence suggest that
drug seeking and drug intake are most likely mediated through the activation of the Hcrt system.
All these evidence suggest that Hcrt may facilitate the expression of many aspects of the
drug addiction cycle. However, it seems that Hcrt have a drastic impact on DA transmission
through the VTA. Peripheral and intra-VTA blockade of HcrtR1 disrupts baseline DA signaling
and reduces baseline DA activity and DA responses to cocaine [227], suggesting that intact Hcrt
neurotransmission is necessary to support normal DA responses to cocaine. Application of Hcrt
in the VTA has been shown to induce DA release in the PFC and NAcc which are a key struc-
ture in the development of drug addiction [180, 204]. Intra-VTA infusions of Hcrt-1 facilitate
DA release to cocaine in the NAcc and induce c-fos activation in VTA DA neurons that project
to the NAcc shell [234]. Thus, Hcrt increases DA neuron activity in the VTA and, in agreement
with a few reports, Hcrt increases both burst and firing of DA neurons [199]. Further, Hcrt KO
mice show reduced levels of basal dopamine in forebrain structure [217] and in NAcc [227] and
reduced evoked dopamine release and uptake in the NAcc following cocaine and morphine in-
jections [204,234]. The DA and Hcrt systems may act synergistically to regulate reward seeking
behaviors.
1.3.6 Brief summary
The hypocretin system is composed of a few thousand neurons restricted in the lateral hy-
pothalamus and the perifornical area. Hypocretin-containing neurons project throughout the
brain with a prominent input to basal forebrain structures involved in arousal, stress, motiva-
tion, and reward [73, 148]. Their interaction with autonomic, neuroendocrine and neuroreg-
ulatory systems [75, 148, 235–242] strongly suggests they act as neuromodulators in a wide
variety of neural circuits. The hypocretins have been implicated in the modulation of nora-
drenergic [103, 110, 114], cholinergic [106], serotoninergic [105, 243], histaminergic [116, 244] and
dopaminergic systems [104, 199] and in the regulation of the hypothalamic-pituitary-adrenal
(HPA) axis [75, 241, 245–248]. Evidence from multiple experiments indicates that Hcrt neurons
in the lateral hypothalamus receive inputs from diverse sensory and limbic systems to provide a
coherent output that results in the stability of the states of vigilance [249].
Again, chronic drug intoxication may induce changes in basic needs priorities, and the Hcrt
system may be part of a common mechanism for adapting and/or ranking priorities and eliciting
appropriate levels of alertness to drive attention processes and trigger goal-directed behaviors
according to these new priorities [151].
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1.3.7 Further considerations: The melanin-concentrating hormone (MCH) sys-
tem
Noteworthy, the lateral hypothalamus also hosts in its vicinity the melanin-concentrating hor-
mone (MCH) system. These two systems have distinct distributions and do not overlap [250–
252], but share several similarities. Like the hypocretin system, the MCH neurons sends pro-
jections throughout the brain [253] and MCH peptide binds two different GPCRs, MCH re-
ceptor 1 (MCHR1) and MCH receptor 2 (MCHR2), but only MCHR1 is expressed in rodents.
Activation of both receptors mediates responses through Gi/o, Gq and Gs proteins [254, 255].
Similar to the Hcrt system, it has been implicated in numbers of physiological states, such
as arousal/sleep [256–260], energy metabolism [261–264], and finally in reward-related behav-
iors [265–273].
Both Hcrt and MCH systems are expressed in the hypothalamus which is a key structure
in mediating autonomic and neuroendocrine signaling. Hypocretins and MCH are involved
in the regulation of many physiological states and seem to be complementary in many cases.
In addition, the MCH system interacts with the hypocretin neurons; MCH peptides have an
inhibitory influence on hypocretin neurons [274, 275]. These observations suggest that these
two neuronal populations could directly control sleep-wake regulation, energy expenditure and
motivation for reward.
2 Rationale
Drug addiction is a complex behavior driven by multiple parameters, including genetic and
environmental dispositions, affecting a large range of the population. For the past few years,
drug addiction has been dissected with a special emphasis on the dopaminergic and glutamater-
gic systems. Substances of abuse drastically modify catecholaminergic transmission by inducing
neuronal adaptations following acute or chronic use. Even though major advances have been
leading to a better comprehension of the processes triggered by drug addiction, not all aspects of
the development and expression could be explained regarding dopamine and glutamate. Recent
evidence has shown that the hypocretin system might represent a promising candidate target
for both fundamental research and clinical practice. Drugs of abuse withdrawal symptoms could
be reduced with Modafinil treatment, a medication for narcolepsy. Indeed, Modafinil activates
the hypocretin system, since an increase in c-Fos is observed. In addition, most of narcoleptic
patients treated with amphetamine-like drug do not abuse their medication [214,215], suggesting
that addictive drugs may interact with hypocretins in order to promote reward related behaviors.
Electrophysiological and behavioral data suggest that the hypocretin system, especially Hcrt-
1 and HcrtR1, contributes to the development and the expression of drug addiction. So far, an
increasing number of evidence supports the hypothesis that hypocretins mediate a wide range
of adaptations triggered by drug abuse, considering that either their blockade or absence induce
impaired responses to reward related behaviors. Most of the studies on drug addiction consider-
ing the hypocretin system were carried out on rodents treated with antagonists, mainly with the
HcrtR1 antagonist SB-334867 although it shows low affinity for 5-HT2B and 5-HT2C receptors
and others GPCRs [94]. Only a few reports were performed on constitutive ppHcrt KO mice
and only one report used the hypocretin ablated neurons mice. To our knowledge, no study was
reported with the constitutive preprohypocretin knock out mice regarding cocaine and alcohol.
And transgenic animals are powerful tools to dissect the role of complex neural processes. In
addition, the hypocretin system is well conserved throughout the species, allowing translational
approach to humans. In order to further understand the role of Hcrt in both cocaine- and
alcohol-related behaviors, constitutive ppHcrt KO mice, HET and their WT littermates were
tested for either cocaine, including behavioral sensitization and conditioned place preference, or
social alcohol consumption. The first part of this project was to assess in both male and fe-
male whether constitutive ppHcrt KO mice could develop normal cocaine related behaviors and
whether reduced levels of hypocretins might affect the development of drug-induced responses
compare to their WT littermates. The second part of the present report was to assess alcohol
consumption in female KO, HET and WT mice. In order to measure alcohol consumption, we
used a novel automated apparatus allowing us to monitor a large number of mice for several
consecutive days where social interactions were allowed during the ongoing procedure.
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3 Materials and Methods
3.1 Animals
Founder hypocretin knockout mice, provided by Dr. Yanagisawa (Houston) [129], were on a
C57Bl/6J-129/SvEV background and their offspring were backcrossed with C57Bl/6J mice for
at least eight generations. In our experiments, we used ppHcrt KO, HET and WT mice that
were produced from heterozygous crosses. All animals were housed in a controlled environment
(22 ± 1◦C, humidity 50 ± 5%)and were kept under a reverse light/dark cycle (lights off at 10
am and lights on at 10 pm) with free access to food and water. All experiments were conducted
under the dark phase and were performed in accordance with the Swiss Federal Act on Animal
Protection and Swiss Animal Ordinance and as approved by cantonal ethics committee.
3.2 Genotyping
Genomic DNA was obtained from tail biopsies. Tail biopsies were incubated in TENS buffer
(100mM Tris-HCl pH 8.0, 5mM EDTA-Na2 pH 8.0, 0.5% SDS, 100mM NaCl, 200 µg/ml pro-
teinase K) overnight at 55◦C. After centrifugation, the supernatant was recovered and DNA
was precipitated with isopropanol. Then, DNA was harvested by centrifugation and the pellet
was once washed with 70% ethanol before being resuspended in ddH2O. Mice were genotyped
using PCR amplification with a neo primer 5’-CCG CTA TCA GGA CAT AGC GTT GGC-3’,
or a genomic primer 5’-GAC GAC GGC CTC AGA CTT CTT GGG-3’, and genomic primer
3’-TCA CCC CCT TGG GAT AGC CCT TCC-5’ common to knock out and WT mice.
Figure 3.1: Hypocretin-deficient mice genotyping.
3.3 Locomotor Sensitization
All treatment and behavioral testings were performed during the dark cycle. Prior the start of
the experiment, males and females, aged between 10 and 18-weeks, were habituated for 15min
in a large circular openfield (⊘ = 72.5 cm). Mice were then tested for 7 consecutive days during
37
3. MATERIALS AND METHODS 38
which all animals were further habituated to the openfield paradigm for 15 min prior to the 60
min testing session. All animals were challenged with intraperitoneal (ip) injections of saline on
day 1 and either with 15 mg/kg cocaine or with saline as the control condition from day 2 to
day 7. Hcrt KO mice (n = 30), HET (n = 30) and WT littermates (n = 31) were given either
cocaine (15 mg/kg) or saline (see table 3.1 for details). Mice were first exposed to the arena
for 15 min before injection and following injection, animals were put back in the arena where
they were videotaped for 1h. Locomotor activity was then assessed with Ethovision 3.0 software
(Noldus R©).
Treatments Genotypes Males Females
Saline
WT 8 8
HET 8 6
ppHcrt KO 9 7
Cocaine
15 mg/kg
WT 8 7
HET 9 7
ppHcrt KO 8 7
Table 3.1: Locomotor sensitization. Summary of the number of animals used in each group
Figure 3.2: Locomotor sensitization paradigm. The locomotor sensitization paradigm consisted of a large circular
arena. The distances traveled of each animal in the arena were assessed with Ethovision 3.0 software (Noldus R©).
3.4 Locomotor Sensitization with Running Wheel
All treatment and behavioral testings were performed during the dark cycle. Prior the start of
the experiment, mice were first habituated to the running wheels for 5 consecutive days in a
120 min session in order to allow mice to learn how to coordinate their movements and speed
with wheel running. The number of wheel turns was recorded every 5 min epoch in a 120 min
session. Following two days of rest in their home cage, all animals were further habituated for
60 min prior the 60 min testing session for 7 consecutive days. The number of wheel turns was
recorded every 5 min epoch for each 60 min session.
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Genotypes Females
WT 6
HET 7
ppHcrt KO 5
Table 3.2: Locomotor sensitization with running wheel. Summary of the number of animals used in each group
Figure 3.3: Running Wheel apparatus. The running wheel apparatus consisted of a home cage supplemented with
a wheel. The running wheel apparatus provides a measurement of voluntary locomotor activity over a fixed period of
time.
3.5 Evaluation of Motor Skills with Rotarod
KO mice, HET and WT females were tested in a rotarod to assess their locomotor skills. An-
imals were tested for 3 consecutive days. The first day, ten- to twelve-weeks aged mice were
trained with 5rpm in a 5min session. The second day, mice were tested for 8 different speeds
(5, 10, 15, 20, 25, 30, 35, 40rpm) in a 2 min session. The last day mice were tested using the
acceleration mode (5 - 60rpm) for a 600 s (10 min) session. For each testing mode, each mouse
was given 3 trials.
Genotypes Females
WT 6
HET 7
ppHcrt KO 5
Table 3.3: Rotarod. Summary of the number of animals used in each group
Figure 3.4: Rotarod apparatus. The rotarod apparatus consist of beam that can rotate at fixed or accelerating speed.
Mice are placed on the beam and the latency to fall provides a measurement of their motor coordination.
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3.6 Conditioned Place Preference
The paradigm consisted of a Y-shape box with two-equal sized compartments (15 x 15 x 15
cm) separated by a neutral triangular space. The two compartments had different visual (dots
vs stripes) and tactile (metal grid floor vs spotted floor) cues. The place conditioning schedule
was conducted in four phases: habituation, preconditioning test, conditioning and post con-
ditioning test. The habituation session was performed to familiarize animals to handling and
manipulation as well as to the arena; mice were allowed to freely explore the arena for 20 min.
The preconditioning test consisted of a 20 min session during which mice were recorded using a
digital video camera and the time spent in each compartment was assessed with Ethovision 3.0
software (Noldus R©). Any animal spending more than 70% of total time in one compartment
were excluded to avoid confounding factor of endogenous preference or aversion. The condition-
ing phase was performed for 4 consecutive days. Each day, animals were treated with either
cocaine 15 mg/kg or saline and confined to one compartment for 20 min in the morning session
and treated with saline (intraperitoneally) and confined to the other compartment for 20 min
in the evening session. Post conditioning test consisted of a 20 min session in which mice were
recorded using a digital video camera and the time spent in each compartment was assessed by
Ethovision 3.0 software (Noldus R©). Mice were also exposed to the arena 2 weeks after posttest
to assess whether they still exhibit a preference for the compartment previously associated with
cocaine. Mice aged between 10 and 18-weeks were distributed as the following groups: ppHcrt
KO (n = 38), HET (n = 34) and WT mice (n = 33) were given either cocaine or saline (for
more details, see table 3.4).
Treatments Genotypes Males Females
Saline
WT 11 8
HET 9 7
ppHcrt KO 8 7
Cocaine
15 mg/kg
WT 12 7
HET 10 8
ppHcrt KO 11 7
Table 3.4: Conditioned place preference. Summary of the number of animals used in each group
Figure 3.5: Conditioned place preference apparatus. The paradigm consisted of a Y-shape box with two-equal sized
compartments (15 x 15 x 15 cm) separated by a neutral triangular space. The two compartments had different visual
(dots vs stripes) and tactile (metal grid floor vs spotted floor) cues.
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3.7 IntelliCage R©
3.7.1 IntelliCages paradigm description
The IntelliCage (IC) apparatus is a novel automated system assessing spontaneous behavior in
social groups of mice. The apparatus provides four right-angled triangular recording chambers
that fit into the corners of the housing cage (55 x 37.5 cm at the base, 58 x 40 cm at the top,
20.5 cm for height). Each recording chambers contains two openings, each permitting access to
bottles. Prior the start of the experiment, animals were implanted with subcutaneous transpon-
ders which enable recognition of each individual at the entrance of each corner via an antenna.
Each recording chamber monitored animals’ visits, nosepokes and licks which were implemented
through the software provided with the IntelliCage. Four triangular mouse shelters were placed
in the center of each cage allowing mice free access to food.
(a) (b)
Figure 3.6: IntelliCage apparatus. (a). Illustration of the IntelliCage apparatus. (b). Schematic drawing of the Intel-
liCage apparatus shows the four triangular corners with a ring antenna enabling recognition of each animal transponder.
The circular antenna give access to the inner chambers, each holding two bottles where animal’s nosepokes and licks
were recorded. In the middle, plastic housing shelters provide access to the food hopper.
3.7.2 Experimental design
The IntelliCages allow hosting and recording large social groups of mice. To avoid or minimize
any aggressive behavior or any bias resulting from hierarchy between animals, only female mice
were used. In the present report, each IC contained 10 mice with balanced number of ppHcrt KO,
HET and WT mice. The IC procedure was divided in different stages. In order to familiarize
mice with the apparatus, animals were exposed in the IntelliCage for one week where they were
allowed to freely explore each corner in which water was available. Animals exhibiting any
preference for one corner in terms of proportion of visits, nosepokes and licks were discarded
from the experiment. After one-week habituation and two days of resting in home cage, different
liquid solutions were introduced in the IntelliCage apparatus. Each corner corresponds to one
specific solution which was the following: 1) water, 2) quinine 1mM or 0.2% saccharine, 3) alcohol
8% w/v and 4) alcohol 16% w/v. Different alcohol solutions were used to test the propensity of
mice to drink alcohol and quinine was used to test gustatory sensitivity. Animals were exposed
in the IntelliCage for 3 sessions which consisted of 3 consecutive days exposure in IC followed
by 4 days rest in their home cages. Then animals experienced two weeks of alcohol abstinence,
before being exposed in the IC apparatus for 3 consecutive days where alcohol 8% w/v or 16%
w/v were freely available in order to test whether mice exhibit a relapse-like behavior.
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Genotypes Females
WT 7
HET 7
ppHcrt KO 6
Table 3.5: IntelliCages. Summary of the number of animals used in each group
3.8 Data and Statistical Analysis
Data shown are presented as group (WT, HET and ppHcrt KO) mean ± SEM. Normalization of
the cocaine sensitization data is obtained by dividing the difference between the distance traveled
post injection and the distance traveled prior injection with the total locomotor activity during
both periods (prior−postprior+post).
Statistical analyses were performed with the R program (version 2.11.1). Significance thresh-
old is considered at α-level<0.05. A repeated measures ANOVA was performed followed by the
TukeyHSD post hoc test or by the Student’s t test. If the data did not reach ANOVA as-
sumption criteria, data were first transformed. If the transformed data did not follow a normal
distribution, the equivalent non parametric statistical test (Kruskal-Wallis) was performed.
4 Results
4.1 Behavioral sensitization in ppHcrt KO mice
Previous studies have demonstrated that hypocretin disruption led to a reduction of the drug
induced increased locomotor activity. [204, 216–218]. Further, rats treated with the HcrtR-1
antagonist SB-334867 displayed a reduced sensitization to the psychostimulant-induced hyper-
locomotion [200, 218]. Finally, the Hcrt levels have been shown to be differentially regulated in
male and female mice. Therefore, we performed an exhaustive study with male and female mice
of the three genotypes, WT, HET and ppHcrt KO. All animals were injected with cocaine at
the dose of 15 mg/kg ip or with saline, and their locomotor activity was assessed for seven daily
sessions of 60 min. Session 1 consisted of saline treatment to assess the basal locomotor activ-
ity and from session 2 to session 7, animals were treated with either cocaine or saline (control
condition).
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Figure 4.1: Locomotor sensitization in males. Locomotor activity was assessed after ip injection of 15 mg/kg cocaine
(filled symbols) or saline (open symbols) in WT (square), HET (triangle) and ppHcrt KO mice (circle). Results are
displayed as the mean ± SEM of the total distance traveled during 1h test session. Asterisks, dollars and sharps denote
a p-value<0.05 relative to session 1. Tukey post hoc test: * p-value<0.05, ** p-value<0.01 and *** p-value<0.001
versus session 1 in the WT cocaine treated group. # p-value<0.05, ## p-value<0.01 and ### p-value<0.001 versus
session 1 in the KO cocaine treated group. $ p-value<0.05, $$ p-value<0.01 and $$$ p-value<0.001 versus session 1
in the HET cocaine treated group.
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Basal locomotor activities on session 1 in the group assigned in the cocaine treatment (wt:
14089 ± 2119 cm, n = 8; ppHcrt KO: 12444 ± 906 cm, n = 8; het: 13345 ± 1013 cm, n = 9;
p-value>0.05) were statistically not different from the saline-treated groups (WT: 14339 ± 2251
cm, n = 8; ppHcrt KO: 11902 ± 1883 cm, n = 9; HET: 13799 ± 1752 cm, n = 8; post hoc test:
p-value>0.05) (figure 4.1). All the control groups did not exhibit any significant increase in
their locomotor activity after saline administration over sessions (post hoc test: p-values>0.05).
WT and HET animals showed a slight increase in the distance traveled during session 7 which
was not significant relative to baseline values (session 1; post hoc test: p-values>0.05). WT
mice treated with cocaine exhibited a robust sensitization; the distances traveled in the arena
were significantly different from the first cocaine administration (session 2; post hoc test: p-
value<0.001) to the last cocaine treatment (session 7; post hoc test: p-value<0.001) relative to
session 1 (F(1,308)(treatments)=563.6, p-value<0.001). KO mice exhibited a delayed and atten-
uated locomotor sensitization to cocaine injections ((F(2,308)(genotypes)=36.7, p-value<0.001));
mice displayed a significant increased locomotor activity from session 4 to session 7 (compared
to session 1). Noteworthy, HET animals exhibited an intermediate response to cocaine-induced
hyperlocomotion (figure 4.1). On session 7, all mice exhibited similar locomotor activity (58389
± 7359 cm for WT, 45834 ± 5483 cm for HET and 42303 ± 6106 cm for KO mice). No statistical
differences were observed between genotypes (post hoc test: p-value>0.05).
4.1.2 Females
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Figure 4.2: Locomotor sensitization in females. Locomotor activity was assessed after ip injection of 15 mg/kg cocaine
(filled symbols) or saline (open symbols) in WT (square), HET (triangle) and ppHcrt KO mice (circle). Results are
displayed as the mean ± SEM of the total distance traveled during 1h test session. Asterisks, dollars and sharps denote
a p-value<0.05 relative to session 1. Tukey post hoc test: * p-value<0.05, ** p-value<0.01 and *** p-value<0.001
versus session 1 in the WT cocaine treated group. # p-value<0.05, ## p-value<0.01 and ### p-value<0.001 versus
session1 in the KO cocaine treated group. $ p-value<0.05, $$ p-value<0.01 and $$$ p-value<0.001 versus session 1
in the HET cocaine treated group.
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No differences were detected in basal locomotor activity between groups (session 1) (figure 4.2).
In the saline-treated groups, the traveled distances remained stable over sessions. No differ-
ences were observed between genotypes (post hoc test: p-value>0.05). In the cocaine-treated
groups, all animals displayed a significant cocaine-induced hyperlocomotion (F(1,252)(treatments)
=476.6, p-value<0.001). For all cocaine-treated groups, the traveled distances in the arena be-
came significantly different from session 1 after the third injection of cocaine (session 4; post hoc
test: p-value<0.05). Even though no robust differences are observed between genotypes over
sessions, statistical analysis highlighted a significant genotype effect (F(2,252)(genotypes)=5.35,
p-value<0.01) indicating that HET exhibited a higher locomotor activity following saline and
cocaine injections than that WT and KO.
4.1.3 Comparison between males and females
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Figure 4.3: Locomotor sensitization: Comparison males vs females. Locomotor activity was assessed after ip
injection of 15 mg/kg cocaine (filled symbols) or saline (open symbols) in WT (square), HET (triangle) and ppHcrt
KO mice (circle) in males (blue) and females (red). Results are displayed as the mean ± SEM of the total distance
traveled in 1h test session. For statistical analysis, see figures 4.1 for males and 4.2 for females.
Figure 4.3 summarizes all the data collected with male and female mice. On session 1, the
distances traveled in the one hour testing session by males and females were similar irrespective
of genotypes. In the saline-treated groups, the distances traveled were maintained stable in all
groups over the 7 sessions. However, male ppHcrt KO tend to exhibit lower locomotor activity
relative to all groups, even compared to female ppHcrt KO (F(2,560)(gender x genotype)=9.0, p-
value<0.001). Following the first cocaine administration (session 2) and after repeated exposures
to cocaine (15 mg/kg), all animals did exhibit hyperlocomotion (F(1,560)(treatments)=1097.6,
p-value<0.001 and F(6,560)(sessions)=45.9, p-value<0.001). However, WT males exhibited a
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more robust cocaine behavioral sensitization and KO males did show a delayed and attenuated
behavioral sensitization compared to the other cocaine-treated groups, which was highlighted
by a significant genotype effect (F(2,560)(genotypes)=35.3, p-value<0.001).
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4.2 Amplitude of behavioral sensitization in ppHcrt KO mice
Before each test session, animals were exposed in the arena during 15 min and the locomotor
activity was assessed. Immediately after ip injections of either cocaine or saline, animals were
returned to the arena for the 60 min test session. In order to evaluate the amplitude of the
behavioral sensitization, the locomotor activity of the first 15 min of each test session was re-
lated to the daily activity (for more detail, see section 3.8). Figures 4.4, 4.5 and 4.6 represent
normalized data. Negative values mean a decrease in the distance traveled during the first 15
min post injection compared to the 15 min of habituation before the injection. In contrast, pos-
itive values indicate an increase in the distance traveled during the first 15 min post injection
compared to the 15min of habituation before the injection.
4.2.1 Males
1 2 3 4 5 6 7
-0.6
-0.4
-0.2
0.0
0.2
0.4
0.6
Sessions
5H
ODW
LYH
YD
OXH
P
HD
Q
VH
P
* *
* *
*
*
#
ƃ
WT saline
WT cocaine
HET saline
HET cocaine
KO saline
KO cocaine
Figure 4.4: Locomotor sensitization in males: Data normalization. Representation of normalized data between
the first 15 min of the test session and the 15 min prior the injection. Groups treated with 15mg/kg cocaine are
represented by filled symbols and control groups by open symbols, each groups including WT (square), HET (triangle)
and ppHcrt KO mice (circle). Values under zero represent reduced locomotor activity and above zero represent increased
activity following cocaine injections. Results are displayed as the mean ± SEM of normalized data. Asterisks denote
a p-value<0.05 relative to session 1. Sharp denotes a p-value<0.05 versus WT cocaine-treated group, HET cocaine
treated group and the other sessions of KO cocaine treated group.
On session 1, all groups of mice were treated with saline injections to assess the basal activity
(figure 4.4). The basal locomotor activity was similar in all male groups. The saline-treated
groups displayed a reduced locomotor activity following the treatment over sessions. In con-
trast, the cocaine-treated groups demonstrated an increase in the distance traveled during the
first 15 min post injection compared to the 15 min habituation prior to cocaine administration
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(F(1,308)(treatments)=1143.1, p-value<0.001). Behavioral sensitization amplitudes were similar
in WT and HET, an observation underestimated on figure 4.1, where HET male mice did show
a reduced locomotor activity induced by cocaine administration compared to WT littermates.
Interestingly, ppHcrt KO mice displayed a behavioral sensitization to cocaine with a similar am-
plitude to that observed in WT and HET mice. Only session 2 remained significantly different
compared to session 1 and sessions 4 to 7 (F(2,308)(genotypes)=7.0, p-value<0.01), confirming
that KO males exhibit a reduced and delayed sensitization to the locomotor effects of cocaine,
but to a lesser extent than initially suggested on figure 4.1.
4.2.2 Females
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Figure 4.5: Locomotor sensitization in females: Data normalization. Representation of normalized data between
the first 15 min of the test session and the 15 min prior the test session. Groups treated with 15mg/kg cocaine are
represented by filled symbols and control groups by open symbols, each groups including WT (square), HET (triangle)
and ppHcrt KO mice (circle). Values under zero represent reduced locomotor activity and above zero represent increased
activity following injections of either cocaine or saline. Results are displayed as the mean ± SEM of normalized data.
Asterisks denote a p-value<0.05 relative to session 1.
Consistent with our former observations, the basal locomotor activity following saline adminis-
tration on session 1 was reduced in all females (post hoc test: p-value>0.05). In the saline-treated
groups, the locomotor activity was similar over sessions (figure 4.5; post hoc test: p-value>0.05).
In the cocaine-treated groups, all mice exhibited hyperlocomotion following acute and chronic
intermittent exposure to cocaine (F(1,252)(treatments)=14.2, p-value<0.001). No statistical dif-
ferences were observed between ppHcrt KO, HET and WT females (F(2,252)(genotypes) =0.1,
p-value>0.05), which is consistent with our previous observations on figure 4.2.
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4.2.3 Comparison between males and females
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Figure 4.6: Locomotor sensitization: Comparison males versus females. Locomotor activity was assessed after ip
injection of 15 mg/kg cocaine (filled symbols) or saline (open symbols) in WT (square), HET (triangle) and ppHcrt
KO mice (circle) in males (blue) and females (red). Results are displayed as the mean ± SEM of the total distance
traveled in 1h test session. Asterisks denote a p-value<0.05 relative to session 1. Sharp denotes a p-value<0.05 versus
WT cocaine-treated group, HET cocaine treated group and the other sessions of KO cocaine treated group.
Behavioral sensitization amplitudes in males and females are represented on figure 4.6. No statis-
tical differences were observed between gender (F(1,560)(gender)=1.6, p-value>0.05). Behavioral
sensitization amplitudes were significantly affected by genotypes (F(2,560)(genotypes)=9.1, p-
value<0.001), meaning that KO animals seems to have a lower locomotor activity following
saline and cocaine injections, and (F(1,560)(treatments)=1536.9, p-value<0.001), indicating that
the amplitude of the cocaine-treated groups were statistically different relative to the saline-
treated groups.
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4.3 Behavioral sensitization with running wheel in female ppHcrt
KO mice
It has been reported that wheel running augments drug-induced locomotor sensitization. In
order to test whether the environment has an influence on behavioral sensitization in female, we
used running wheels as an alternative to the openfield. To avoid any confounding effects due
to novelty, animals were first trained for five consecutive days to learn how to coordinate their
movements and speed with wheel running. Then, animals followed a similar procedure as the
locomotor sensitization procedure, except for the duration of the habituation phase prior each
test session which was extended to one hour.
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Figure 4.7: Locomotor sensitization with running wheels in females Locomotor activity was assessed before and
after ip administration of (a). saline injections, (b). the first cocaine injection (15 mg/kg) and (c). after chronic
intermittent treatment with cocaine (15 mg/kg) in WT (filled square; n = 6), HET (filled circle; n = 7) and ppHcrt
KO (filled triangle; n = 5) mice. Results are displayed as the mean ± SEM of the total distance traveled during
habituation (before) and the test session (after).
The basal locomotor activity in running wheel was assessed in session 1 (figure 4.7a). The
distances traveled during habituation (before) and following saline injection (after) were sim-
ilar in HET and WT animals. No statistical differences were found between WT and HET
(F(1,30) (tests)=0.1, p-value>0.05). The distances traveled by ppHcrt KO mice during habitua-
tion and the test session were reduced compared to both WT and HET (F(2,30)(genotypes)=3.5,
p-value=0.044). However, in our sample size, multiple comparison did not highlight any statis-
tical differences between groups (post hoc tests: p-value>0.05).
Following the first ip administration of cocaine, WT, HET and ppHcrt KO female mice did
not exhibit any hyperlocomotion (figure 4.7b) (F(1,30)(tests)=0.2, p-value>0.05). Even though
the distances traveled by ppHcrt KO mice were reduced relative to WT mice, these differences
were not significant (F(2,30)(genotypes)=2.9, p-value=0.07).
After repeated exposures to cocaine, WT, HET and ppHcrt mice exhibited behavioral sen-
sitization in running wheel (figure 4.7c). WT and HET mice showed a similar locomotor activ-
ity. The distances traveled by ppHcrt KO mice seemed to be reduced compared to HET and
WT mice. However, these differences were not significant F(1,30) (tests)=3.3, p-value=0.07 and
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F(2,30)(genotypes)=2.6, p-value=0.09 in our sample size.
In order to compare data obtained in the locomotor sensitization procedure in a openfield
with the present data, normalization was performed (see section 3.8 for more details). As pre-
viously mentioned, negative values mean a decrease in the distance traveled during the first
15 min post injection compared to the 15 min of habituation before the injection. In contrast,
positive values indicate an increase in the distance traveled during the first 15 min post injection
compared to the 15min of habituation before the injection.
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Figure 4.8: Locomotor sensitization with running wheels in females: Data Normalization. Representation of
normalized data between the first 15 min of the test session and the 15 min prior the test session. All groups were
treated with 15mg/kg cocaine and WT are represented with filled square(n = 6), HET with filled circle (n = 7) and
ppHcrt KO mice with filled triangle (n = 5). Values under zero represent reduced locomotor activity and above zero
represent increased activity. Results are displayed as the mean ± SEM of normalized data.
The basal locomotor activity was assessed on session 1. The distance traveled in running
wheel was similar between all genotypes; no statistical differences were observed (figure 4.8;
post hoc test: p-value>0.05). From session 2 to session 7, female mice were treated intraperi-
toneally with 15 mg/kg cocaine following the daily habituation phase. On session 2, cocaine
injection did not induce any changes in the locomotor activity between genotypes; WT, HET
and KO mice did not exhibit any hyperlocomotion. From session 3, ppHcrt KO mice and
to a lower extent WT exhibited a slight increase in their locomotor activity following cocaine
injection (F(6,105)(sessions)=3.5, p-value<0.01). In contrast, HET animals did not show any
cocaine-induced locomotor sensitization (F(2,560)(genotypes)=45.9, p-value<0.01). These results
contrasts with our previous observations (figure 4.5).
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4.4 Deficit in coordination at high speed on the rotarod in female
ppHcrt KO mice
The locomotor sensitization procedure with running wheel points out locomotor differences be-
tween KO and WT female mice. To test whether ppHcrt KO mice exhibit deficit in locomotor
skills, we used the rotarod paradigm. Here, fixed and accelerating modes were performed on
WT, HET and KO mice.
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Figure 4.9: Evaluation of motor skills in females on the rotarod. Latency to fall off the rotarod in [s] is represented
for (a) fixed speed mode. Results are displayed as the mean of the latency to fall in [s] ± SEM. Tukey post hoc
test: * p-value=0.06 and # p-value<0.05 relative to 5, 10, 15, 20 and 25 rpm in WT and KO mice, respectively.
$ p-value<0.05 and $$ p-value<0.01 relative to 5, 10, 15 and 20 rpm in HET. (b). accelerating mode. Results are
displayed as the mean of the latency to fall in [s] ± SEM.
On the fixed speed mode (figure 4.9a), ppHcrt KO, HET and WT mice performed well on
speeds up to 20 rpm. At 25 rpm, HET animals seemed to fall off earlier than both ppHcrt
KO and WT mice. However, no significant differences were observed between WT, HET and
ppHcrt KO mice (F(2,120)(genotypes)=2.5, p-value=0.08). Although no statistical difference
was detected, HET and ppHcrt KO mice tended to have more difficulty to stay on the rotarod
compared to WT animals. At the highest speed, all mice fell off before the end of the trial
(F(7,120)(speeds)=13.5, p-value<0.001). At 40 rpm, the latency to fall for WT, HET and ppHcrt
KO were 68.3 ± 20.8 s, 63.4 ± 19.4 s and 68.0 ± 18.0 s, respectively.
On the accelerating mode (figure 4.9b), ppHcrt KO mice seemed to fall off earlier than WT
and HET mice. WT, HET and ppHcrt KO mice fell at 362.2 ± 41.1 s, 356.9 ± 43.0 s and 287.2
± 20.8 s, respectively. However, the latencies to fall between genotypes were not statistically
different (F(2,15)(genotypes)=1.2, p-value>0.05). The average speed at which mice fell off was
for WT, HET and ppHcrt KO mice at 38 ± 4 rpm, 37 ± 4 rpm and 32 ± 2 rpm respectively. No
statistical differences were found in speed between genotypes (F(2,15)(speed)=1.1, p-value>0.05).
Comparison of data acquired from fixed speed and accelerating tasks showed similar results for
ppHcrt KO and WT mice in both tests. In contrast, HET were able to run faster on the
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accelerating mode than the fixed speed task (figure 4.9a).
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4.5 Conditioned place preference in ppHcrt KO mice
It has been reported that ppHcrt KO mice did not exhibit any preference for the compartment
previously paired with repeated morphine injection [204, 216]. To determine whether ppHcrt
KO mice would exhibit a preference for cocaine, we tested mice in an unbiased CPP procedure.
During the pretest procedure, animals were allowed to freely explore the entire arena in a drug
free state. The time spent in the compartment in which conditioning would be proceeded was
assessed. After four repeated conditionings either with saline or cocaine, animals were exposed
again in the entire arena in a drug free state and the time spent in the compartment paired
with repeated conditionings was monitored. The graphs below represent an histogram of the
time spent in the compartment associated with repeated saline (control condition) or cocaine
injections during pretest and posttest (figure 4.10a) and the score (figure 4.10b), which is defined
as the difference between the time spent in the compartment paired with cocaine during posttest
minus the time spent during pretest.
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Figure 4.10: Conditioned Place Preference in males. Cocaine induced a rewarding effect in WT, HET and KO mice.
(a). The results are displayed as the time spent in [s] in the compartment associated with repeated cocaine or saline
injections during pretest and posttest. Each bar represents the mean time ± SEM of 8-12 mice. Tukey post hoc test: *
p-value<0.05 and *** p-value<0.001. (b). Data are represented by the scores, defined by the difference in [s] between
the postconditioning phase and the preconditioning phase. Each bar represents the mean time ± SEM of 8-12 mice.
Tukey post hoc test: * p-value<0.05.
During pretest, all mice spent similar amount of time in the compartment of reference; no sta-
tistical differences were observed (post hoc test: p-value>0.05). In the saline-treated groups,
the time spent in the compartment associated with saline injections were similar to pretest
(post hoc test: p-value>0.05). In the cocaine-treated groups, all animals exhibited a robust
conditioned place preference (F(1,110)(treatments)=15.2, p-value<0.001); however the rewarding
effect of cocaine following tended to be more robust in ppHcrt KO and HET mice compared to
WT, although these differences were not significant (F(2,110)(genotypes)=1.2, p-value=0.052).
The time spent in the compartment paired with cocaine injections during posttest in WT, HET
and ppHcrt KO mice were 482 ± 32 s, 592 ± 26 and 592 ± 51 s respectively compared to pretest
(339 ± 23 s for WT, 331 ± 34 for HET and 342 ± 20 s for KO).
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The score was 250 ± 42 s for ppHcrt KO mice , 251 ± 41 s for HET and 143 ± 32 s for WT
mice. The score was statistically different relative to saline control groups (p-value<0.05). The
control group did not exhibit any statistical preference or aversion after repeated pairings with
saline; the time spent in the compartment associated with the treatments during the pretest
and posttest were similar (figure 4.10b; p-value>0.05).
We also assessed the locomotor activity during both pretest and posttest by measuring the
distance traveled in the conditioning box.
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Figure 4.11: Conditioned Place Preference in males: Distance traveled in the arena during pretest and posttest.
The distance traveled in the arena was measured during pretest and posttest to evaluate exploratory behavior. The
distances traveled in the arena are represented as bars corresponding to the mean ± SEM of 8-12 mice. Tukey post
hoc test: * p-value<0.05 versus pretest and # p-value<0.05 versus the cocaine-treated groups posttest values.
During pretest, all mice readily explored the arena (figure 4.11). All saline-treated animals
exhibited similar locomotor activities during pretest and posttest sessions. On the other hand,
the cocaine-treated groups exhibited a significant increase in locomotor activity during posttest
(F(1,110)(tests)=15.6, p-value<0.001 and F(1,110)(treatment x tests)=25.0, p-value<0.001), ex-
cept for the ppHcrt KO mice (F(2,110)(genotypes)=18.8, p-value<0.001). The ppHcrt KO mice
did not display any hyperlocomotion following repeated cocaine administrations; the distance
traveled in the arena during posttest was similar to pretest. These results were consistent with
data obtained with the locomotor sensitization procedure on figure 4.1.
4.5.2 Females
This procedure was also performed in females in order to determine whether gender could affect
conditioned place preference in ppHcrt KO mice.
4. RESULTS 56
Ti
m
e 
sp
en
t i
n 
dr
ug
 s
id
e 
[s]
 (m
ea
n ±
 se
m)
WT saline WT cocaine HET saline HET cocaine KO saline KO cocaine0
200
400
600
800
***
*** ***
pretest
posttest
(a) Pretest vs Posttest
Sc
or
e 
[s]
 (m
ea
n ±
 se
m)
WT saline WT cocaine HET saline HET cocaine KO saline KO cocaine−100
0
100
200
300
400
*
*
*
(b) Score
Figure 4.12: Conditioned Place Preference in females. Cocaine induced a rewarding effect in all genotype, as
conditioned place preference was observed in all genotypes. In the control groups, no preference was observed following
repeated saline injections. The results are displayed as the time spent in [s] in the compartment associated with
repeated cocaine injections during pretest and posttest for each group tested. Each bar represents the mean time ±
SEM of 7-8 mice. Tukey post hoc test: * p-value<0.05, and *** p-value<0.001
The time spent in the compartment associated with drug treatment during pretest was
similar in all groups (figure 4.12a). Following conditioning, the saline-treated groups did not
exhibit any significant preference or aversion. In the cocaine-treated groups, all animals ex-
hibited a robust preference for the compartment associated with repeated cocaine injections
(F(1,76)(treatments)=25.0, p-value<0.001), whatever their genotype (F(2,76)(genotypes)=1.9, p-
value>0.05). The time spent during posttest in the compartment paired with repeated cocaine
injections was 551.03 ± 39.14 s for ppHcrt KO mice , 582.43 ± 47.93 s for HET and 663.17 ±
54.92 s for WT mice.
The score was 242 ± 46 s for KO , 283 ± 51 s for HET and 328 ± 41 s for WT mice. The score
was statistically different relative to saline-treated groups (p-value<0.05). The control group did
not exhibit any statistical preference or aversion after conditioning with saline; the time spent
in the compartment during the pretest and posttest were similar (figure 4.12b; p-value>0.05).
The distance traveled in the arena was also measured in pretest and posttest to evaluate the
exploratory behavior of female mice.
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Figure 4.13: Conditioned Place Preference in females: Distance traveled during pretest and posttest. The distance
traveled in the arena was measured during pretest and posttest to evaluate exploratory behavior. The distances ed
in the arena are represented as bars corresponding to the mean ± SEM. Tukey post hoc test: * p-value<0.05 versus
pretest. $ p-value<0.05 versus pretest in WT and HET saline-treated groups. # p-value<0.05 versus posttest, except
the KO cocaine group posttest value.
In the saline-treated groups, WT and HET females did exhibit similar locomotion activity
during posttest compared to pretest. In contrast, the distance traveled by KO mice signifi-
cantly differed from WT and HET posttest values. As expected, the cocaine treatment in-
duced a significant increase in the locomotor activity (F(1,76)(tests)=12.9, p-value<0.001 and
F(1,76)(treatment x tests)=13.1, p-value<0.001), but KO females exhibited a reduced cocaine ef-
fect (F(2,76)(genotypes)=16.9, p-value<0.001) compared to HET and WT littermates (see figure
4.2).
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4.5.3 Comparison males between females
Comparisons between gender are illustrated on figure 4.14.
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Figure 4.14: Conditioned Place Preference: Comparisons males vs females. (a). Cocaine induced a rewarding
effect in all genotypes in males (blue) and females (red), as conditioned place preference was observed in every genetic
background and in both gender. In the control groups, no preference was observed following repeated saline injections.
(b). Preference for the drug associated side is represented by the scores, defined by the difference in [s] between
the postconditioning phase and the preconditioning phase. (c). The distance traveled in the arena was measured
during pretest and posttest to evaluate exploratory behavior. The results are displayed as the time spent in [s] in the
compartment associated with repeated cocaine injections during pretest and posttest for each group tested. Each bar
represents the mean time ± SEM of 7-8 mice. Tukey post hoc test: * p-value<0.05 and * p-value<0.001 versus
pretest. $ p-value<0.05 versus pretest in WT and HET saline-treated groups. # p-value<0.05 versus posttest, except
the KO cocaine group posttest value.
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All the different groups exhibit similar exploratory behaviors during pretest. In the cocaine-
treated groups, the time spent in the compartment paired with cocaine during posttest was in-
creased in all groups. Significant treatments effect (F(1,186)(treatments)=39.2, p-value<0.001),
testing sessions (F(1,186)(tests)=76.1, p-value<0.001) and treatment x testing sessions interac-
tion (F(1,186)(treatments x tests)=61.5, p-value<0.001) were detected. However, the rewarding
effect of cocaine was independent of genetic background (F(2,186)(genotypes)=0.3, p-value>0.05)
and gender (F(1,186)(gender)=1.4, p-value>0.05).
As expected, mice did not exhibit any preference for the environment paired with saline
injection and in the other hand, all mice, whatever their genotype and gender, displayed a pref-
erence for the environment paired with cocaine administration (figure 4.14b).
Considering the distance traveled in the arena (figure 4.14c), WT and HET animals showed
robust locomotor activity in the arena as compared to ppHcrt KOmice (F(2,186)(genotypes)=34.6,
p-value<0.001). Locomotor activity was influenced by the testing sessions (F(1,186)(tests)=28.5,
p-value<0.001) and the treatment (F(1,186)(treatments x tests)=37.3, p-value<0.001). Over-
all, female mice manifested an increased exploratory behavior compared to males in the CPP
apparatus (F(1,186)(gender)=29.1, p-value<0.001).
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4.6 Conditioned place preference in ppHcrt KO mice : a longitudi-
nal approach
A few studies reported that conditioned place preference could be maintained for up to 4 weeks
in rodents [276,277]. The place preference induced by the drug persists in the absence of active
extinction procedure. In the current report, mice were retested two weeks after conditioning
to check whether rewarding effect could be maintained in KO, HET and WT mice. After two
weeks of passive extinction in their home cage, mice were once again exposed to the CPP arena
and the time spent in the compartment previously paired with drug treatment was measured
(summarized in table 4.15).
4.6.1 Males
Treatments Genotypes Pretest Posttest After 2-weeks of passive extinction
Saline
WT 341 ± 16 340 ± 23 336 ± 25
HET 381 ± 13 401 ± 48 210 ± 47
ppHcrt KO 365 ± 26 404 ± 72 254 ± 73
Cocaine
15 mg/kg
WT 339 ± 23 482 ± 32* 499 ± 55*
HET 341 ± 34 592 ± 26* 540 ± 87*
ppHcrt KO 342 ± 20 592 ± 51* 407 ± 64
Table 4.1: Conditioned Place Preference in males. Summary of the time spent in the environment paired with
repeated exposures to either saline or 15 mg/kg of cocaine during pretest, posttest and the testing session 2 weeks
after the last conditioning. Tukey post hoc test: * p-value<0.05 versus pretest.
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Figure 4.15: Conditioned Place Preference in males: Assessment of place preference two weeks after condi-
tioning. Cocaine induced a rewarding effect in all mice. (a). The results are displayed as the time spent in [s] in
the compartment associated with repeated cocaine injection during pretest and posttest for each group tested. (b).
Preference for the drug associated side is represented by the scores, defined by the difference in [s] between the post-
conditioning phase and the preconditioning phase. For both graphs, each bar represents the mean time ± SEM of 8-12
mice. Tukey post hoc test: * p-value<0.05 versus pretest only. # p-value<0.05 versus pretest and posttest.
Two weeks after conditioning, the saline-treated groups spent similar or reduced amount of
time in the compartment associated with repeated saline injections; HET and ppHcrt KO mice
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exhibited a significant reduction in the time spent in the compartment paired with saline in-
jection compared to the pretest. Two weeks after conditioning, WT and HET mice previously
treated with cocaine maintained their preference (F(1,153)(treatments)=42.7, p-value<0.001);
the time spent in the compartment previously paired with cocaine was similar to that obtained
during posttest and was still statistically significant compared to pretest (F(2,153)(tests)= 16.6,
p-value<0.001 and F(2,153)(treatments x tests=16.7, p-value<0.001). In contrast, ppHcrt KO
mice stopped expressing a preference for the compartment previously paired with repeated co-
caine treatments (F(4,153)(genotypes x tests)=3.4, p-value<0.05).
4.6.2 Females
To determine whether passive extinction could be affected by gender, the procedure was re-
peated with female mice (summarized in table 4.2).
Treatments Genotypes Pretest Posttest After 2-weeks of passive extinction
Saline
WT 343 ± 36 360 ± 35 408 ± 77
HET 331 ± 16 321 ± 19 394 ± 98
ppHcrt KO 313 ± 30 333 ± 61 270 ± 65
Cocaine
15 mg/kg
WT 334 ± 46 663 ± 55* 628 ± 80*
HET 299 ± 32 582 ± 48* 593 ± 88*
ppHcrt KO 308 ± 49 551 ± 39* 425 ± 52
Table 4.2: Conditioned Place Preference in females. Summary of the time spent in the environment paired with
repeated exposures to either saline or 15 mg/kg of cocaine during pretest, posttest and the testing session 2 weeks
after the last conditioning. Tukey post hoc test: * p-value<0.05 versus pretest.
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Figure 4.16: Conditioned Place Preference in females: Assessment of place preference two weeks after con-
ditioning. Cocaine induced a rewarding effect in all animals. (a). The results are displayed as the time spent in
[s] in the compartment associated with repeated cocaine injection during pretest and posttest for each group tested.
(b). Preference for the drug associated side is represented by the scores, defined by the difference in [s] between the
postconditioning phase and the preconditioning phase. For both graphs, each bar represents the mean time ± SEM of
8-12 mice. Tukey post hoc test: * p-value<0.05 versus pretest.
After experiencing two weeks of passive extinction, the saline-treated groups spent similar
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amount of time compared to pretest in the compartment of reference. In the cocaine-treated
groups, WT and HET mice maintained a significant place preference for up to two weeks follow-
ing conditioning (F(1,114)(treatments) =32.1, p-value<0.001, F(2,114)(tests)=12.4, p-value<0.001
and F(2,114)(treatments x tests)=11.3, p-value<0.001). In contrast, female ppHcrt KO mice did
not exhibit any robust preference for the context previously paired with repeated cocaine ad-
ministration (F(2,114)(genotypes)=4.2, p-value<0.05).
4.6.3 Comparison between males and females
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Figure 4.17: Conditioned Place Preference in females: Comparison males versus females. Cocaine induced
rewarding effect in all genotype and in both gender, males (blue) and females (red), as conditioned place preference
was observed in all genetic background and in both gender. (a). The results are displayed as the time spent in [s]
in the compartment associated with repeated cocaine injection during pretest and posttest for each group tested.
(b). Preference for the drug associated side is represented by the scores, defined by the difference in [s] between the
postconditioning phase and the preconditioning phase. For both graphs, each bar represents the mean time ± SEM of
8-12 mice. Tukey post hoc test: * p-value<0.05, versus the respective pretest session.
Figure 4.17 summarizes the data collected in males and females. During posttest, cocaine
treatment significantly influenced drug seeking behavior through the different testing sessions
(F(1,267)(treatments)=74.4, p-value<0.001, F(2,267)(tests)=24.1, p-value<0.001 and F(2,267)(treatments
x tests)=26.9, p-value<0.001) whatever their gender and genotypes (F(1,267)(gender)=1.1, p-
value>0.05 and F(2,267)(genotypes)=2.4, p-value=0.08). However, after experiencing two weeks
of passive extinction, both KO females and males did not display any preference for the compart-
ment previously paired with cocaine injections (F(4,267)(genotypes x tests)=3.5, p-value<0.01),
whereas WT and HET did exhibit a robust preference compared to pretest.
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4.7 Drinking behaviors in ppHcrt KO female mice
Only few investigations reported the relationship between alcohol-seeking and taking and the
hypocretin system. Previous approaches showed that Hcrt may play a role in alcohol-related
behaviors. Hcrt-1 injected in the LH stimulated voluntary alcohol intake and pretreatment with
the selective antagonist of HcrtR1 (SB-334867) reduced operant alcohol self-administration and
suppressed a cue induced reinstatement of alcohol-seeking in rats [221, 223–225]. Further, re-
peated intake of alcohol leads to a reduction in Hcrt gene expression in the LH [278]. So far, no
reports described alcohol-related behaviors in constitutive ppHcrt KO mice.
Female ppHcrt KO mice, HET and WT littermates were tested in a novel apparatus where
animals behavior could be monitored in terms of the number and duration of visits, nosepokes
and licks. This apparatus promotes social interactions, as up to twelve mice can be housed in a
single IntelliCage (IC).
4.7.1 Habituation phase with water
During the habituation phase in the IC, only water was provided at each corner. Each mouse
activity was recorded and the number of corner visits was hourly assessed to determine the
exploratory behavior of each genotype in the IntelliCages during the first 48h (figure 4.18a).
It has been reported that hypocretin deficient mice exhibit disrupted sleep/wake cycles which
possibly affect circadian rhythm pattern. This procedure allowed determining how ppHcrt KO
mice behave over time compared to WT mice.
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Figure 4.18: Intellicages R©: Basal activity in females. The total number of visits (a) and licks (b) of ppHcrt KO
mice (filled triangle; n=6), HET (filled circle; n=7) and their WT (filled square; n=8) littermates was measured each
hour of the habituation phase. Here the first 48h of the first habituation session are represented as the mean visits or
licks ± SEM of 6-7 mice. The grey zones represent the dark phase and the non-colored zones illustrate the light phase.
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In the first three hours of exposition in the IC, the activity was enhanced due to novelty-
induced exploration as compared to the following hours (figure 4.18a). The number of corner
visits decreased over time and reached baseline values. The exploratory behavior of WT, HET
and ppHcrt KO mice was similar during the first 48h session in the IC and a circadian rhythm
was observed (F(2,815)(genotypes)=0.8, p-value>0.05). High exploratory behavior was observed
during the dark phase and low activities were found during the light phase (F(47,815)(time)=19.3,
p-value<0.001).
We then looked at the liquid consumption (figure 4.18b). Liquid consumption was variable
between subjects of the same genotype and followed a circadian rhythm. It seemed that HET
females consumed more water than WT and KO mice (F(2,815)(genotypes)=4.1, p-value<0.05).
The number of licks were significantly increased during the dark phase relative to the light phase
(F(47,815)(time)=7.3, p-value<0.001).
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Figure 4.19: Intellicages R©: Habituation phase in females. The daily activity (a) in the IntelliCage apparatus was
measured, as well as the total number of licks (b), was assessed for each genotype (ppHcrt KO mice (white; n=6),
HET (grey; n=7) and WT (black; n=7)) at each corner (corner 1, corner 2, corner 3 and corner 4) for five consecutive
days.
During the habituation phase, WT, HET and ppHcrt KO mice were also tested to assess
whether mice exhibited any preference for the different corners (figure 4.19a). Water was pro-
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vided at each corner. The number of visit was influenced by the time spent in IntelliCages
(figure 4.19a). The number of visits during session 1 was significantly higher compared to the
following sessions (F(4,320)(sessions)=138.6, p-value<0.001). However, it seemed that HET mice
displayed lower amount of visits over sessions (F(4,320)(genotypes)=138.6, p-value<0.001).
In contrast, the number of licks varied between corners and genotypes over the sessions (figure
4.19b). However, the variability between animals tended to decrease over time (F(4,320)(sessions)=2.2,
p-value>0.05). Drinking behavior was influenced by genetic background, it seemed that HET
mice consume more water than WT and KO mice (F(2,320)(genotypes)=5.4, p-value<0.01).
4.7.2 Testing phase with different liquid solutions
Amount of visits and licks
After two days resting in their home cages, animals returned in the IC where novel liquid solu-
tions (water, 1mM quinine, alcohol 8% and alcohol 16%) were introduced (figure 4.21). Each
corner was associated to one specific liquid solution and the number of visits and licks were
averaged from three consecutive days repeated three times with a four days resting period in
the home cage between each session (figure 4.21). In the previous procedure, we observed that
two weeks of passive extinction was sufficient to suppress the preference for an environment
previously paired with cocaine injections in ppHcrt KO animals, so we monitored again mice
behavior two weeks after the last exposure to the IC (the challenge session).
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Figure 4.20: Intellicages R©: Exploration and liquid consumption behaviors in females. Female mice were exposed
in the IntelliCages for 3 testing sessions (session 1 to 3) before experiencing alcohol abstinence for two weeks in their
home cage (session 4). The numbers of visits (a) and licks (b) of WT (square; n=7), HET (circle; n=7) and ppHcrt
KO mice (triangle; n=6) were assessed by counting the number of entries and licks made at the four different corners
where water (black), 1mM quinine (red), alcohol 8% (green) and alcohol 16% (yellow) were provided. The data are
represented as the mean ± SEM. Asterisks denote a p-value<0.05 versus the other solutions.
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The liquid solutions provided at each corner significantly influence the exploratory pattern of
mice (F(3,272)(liquid solutions)=43.3, p-value<0.001). On session 1, the corner associated with
water had the highest number of visits compared to the other liquid solutions corner (figure
4.20a). No statistical differences in the number of visits were found between genotypes within
each corner (post hoc test: p-value>0.05). On sessions 2 and 3, the number of visits was higher
in the water corner compared to the other liquid solutions corners. Interestingly, the number
of visit in the corner paired with alcohol 8% increased slightly, whereas the number of entries
in the corner paired with alcohol 16% decreased (figure 4.20a). On session 2 and 3, ppHcrt
KO mice showed low level of exploratory behavior relative to WT (F(2,272)(genotypes)=9.5,
p-value<0.001). In contrast, HET animals exhibited similar activity to that of WT. During
the challenge session (session 4), ppHcrt KO mice, HET and WT animals exhibited similar
exploratory behaviors compared to session 3. However, ppHcrt KO mice tended to exhibit a
lower exploratory behavior relative to WT and HET, but this tendency was not statistically
significant in our sample size (figure 4.20a).
The amount of licks was influenced by the liquid solutions available (F(3,272)(liquid solu-
tions)=579.2, p-value<0.001) (figure 4.21a). Animals always exhibited a robust preference for
water and a robust aversion for 1mM quinine solution (figure 4.20b). The number of licks for
both water and 1mM quinine were significantly different from the other liquid solutions during
the whole procedure (figure 4.21a). Animals showed a slight preference for alcohol 8% w/v
compared to alcohol 16%. In WT, the number of licks for water decreased over time with a
concomitant increase for alcohol 8% (figure 4.21b). KO mice did also show a reduction in water
consumption, but the number of licks for alcohol 8% and 16% remained stable from session 1
to session 3 (figure 4.21c). HET animals maintained similar pattern of licking behaviors among
each corner over time, except for alcohol 16% (figure 4.21d). During the challenge session, mice
did not demonstrate any robust rebound in the intake for alcohol 8% and alcohol 16% (figures
4.22c and 4.22d). The number of licks was decreased for alcohol 8% and alcohol 16% in WT
and ppHcrt KO (F(2,272)(genotypes)=15.5, p-value<0.001).
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Figure 4.21: Intellicages R©: Liquid consumption behaviors in females. Female mice were exposed in the IntelliCages
for 3 testing sessions (session 1 to 3) before experiencing alcohol abstinence for two weeks in their home cage (session
4). The amounts of licks of WT (black; n=7), HET (grey; n=7) and ppHcrt KO mice (white; n=6) were assessed by
counting the number of licks made at the four different corners (water, 1mM quinine, alcohol 8% and alcohol 16%).
The data are represented as the mean ± SEM. * p-value<0.05 versus the other liquid solutions (preference) and $
p-value<0.05 versus the other liquid solutions (aversion).
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Figure 4.22: Intellicages R©: Detailed liquid consumption behaviors in females. Female mice were exposed in the
IntelliCages for 3 testing sessions (session 1 to 3) before experiencing alcohol abstinence for two weeks in their home
cage (session 4). The amounts of licks of WT (black; n=7), HET (grey; n=7) and ppHcrt KO mice (white; n=6) were
assessed at the four different corners: (a). water, (b). 1mM quinine, (c). alcohol 8% and (d). alcohol 16%). The data
are represented as the mean ± SEM.
Proportion of visits and licks
We previously reported that cocaine sensitization was similar among each genotype after nor-
malization of the data. In order to check whether the slight differences observed here were
correlated to the total activity in the IntelliCage, the numbers of visits observed in each corner
were related to the total number of visits performed during each session (figure 4.23).
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Figure 4.23: IntelliCages R©: Proportion of visits and licks in females. Female mice were exposed in the IntelliCages
for 3 testing sessions (session 1 to 3) before experiencing alcohol abstinence for two weeks in their home cage (session
4). The proportions of visits (a) and licks (b) of WT (square; n=7), HET (circle; n=7) and ppHcrt KO mice (triangle;
n=6) were assessed at the different corners, where water (black), 1mM quinine (red), alcohol 8% (green) and alcohol
16% (yellow) were provided, are represented as the mean ± SEM. Asterisk denote a p-value<0.05.
The proportion of visits demonstrated that ppHcrt KO mice did exhibit similar exploratory
behavior relative toWT and HET over time in each corner (F(2,272)(genotypes)=0.03, p-value>0.05)
(figure 4.23a). The corner associated with water was significantly preferred compared to the
other corners (F(3,272)(liquid solutions)=239.7, p-value<0.001) and the proportion of visits re-
mained stable in each corner. Surprisingly, the corner paired with alcohol 16% was the least
visited corner. During the challenge session (session 4), animals did not exhibit any difference
in proportion of visits compared to session 3, meaning that no relapse for alcohol-seeking was
observed following two weeks of alcohol abstinence. All animals kept exhibiting a preference for
the water corner and an aversion for the corner paired with alcohol 16%. The proportion of visits
remained stable in the corners paired with alcohol 8% and 1mM quinine (F(3,272)(sessions)=0.08,
p-value>0.05).
The number of licks was also normalized with the total number of licks of the four corners
(figures 4.23b, 4.24 and 4.25). When the data were normalized, no statistical differences in liquid
consumption were observed between the different genetic background (F(2,272)(genotypes)=1.3,
p-value>0.05). However, the nature of the liquid solutions influenced the licking behavior, all
animals preferring water over the three others liquid solutions (F(3,272)(liquid solutions)=783.3,
p-value<0.001) (figure 4.24). And the proportion of licks for 1mM quinine was significantly
lower compared to the other solution from session 1 to session 3. During the challenge session,
the proportion of licks was not statistically different from the other sessions for water, quinine
and alcohol (8% and 16%), demonstrating no relapse for alcohol (figure 4.25).
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Figure 4.24: Intellicages R©: Liquid consumption behaviors in females. Female mice were exposed in the IntelliCages
for 3 testing sessions (session 1 to 3) before experiencing alcohol abstinence for two weeks in their home cage (session
4). The proportions of licks of WT (black; n=7), HET (grey; n=7) and ppHcrt KO mice (white; n=6) were assessed
at the four different corners (water, 1mM quinine, alcohol 8% and alcohol 16%). The data are represented as the mean
± SEM. Tukey post hoc test: * p-value<0.05 versus the other liquid solutions (preference) and $ p-value<0.05 versus
the other liquid solutions (aversion).
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Figure 4.25: Intellicages R©: Detailed liquid consumption behaviors in females. Female mice were exposed in the
IntelliCages for 3 testing sessions (session 1 to 3) before experiencing alcohol abstinence for two weeks in their home
cage (session 4). The proportions of licks of WT (black; n=7), HET (grey; n=7) and ppHcrt KO mice (white; n=6)
were assessed at the four different corners: (a). water, (b). 1mM quinine, (c). alcohol 8% and (d). alcohol 16%).
The data are represented as the mean ± SEM.
The latency to first visit and lick
In order to check whether mice learned to discriminate between corners and the latency to first
visit and first lick was assessed in the three testing sessions and during the last challenging
session (session 4).
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Figure 4.26: IntelliCages R©: Latency to first visit and lick at the four corners. Female mice were exposed in the
IntelliCages for 3 testing sessions (session 1 to 3) before experiencing alcohol abstinence for two weeks in their home
cage (session 4). WT (square; n=7), HET (circle; n=7) and ppHcrt KO mice (triangle; n=6) latency to first visit (a)
and lick (b) were measured in the different corners where water (black), 1mM quinine (red), alcohol 8% (green) and
alcohol 16% (yellow) were provided. The data are represented as the mean ± SEM.
Animals readily explored each corner during the first two hours systemically (figure 4.26a).
The latency to first visit was similar in all genotype from session 1 to session 3 for all corners
(F(2,272)(genotypes)=0.4, p-value>0.05). All mice displayed low latencies to first explore corners
paired with water, quinine, alcohol 8% and an increased latency for first exploring the corner of
alcohol 16%. During the challenge session, the latency to first visit the corner paired with water
and quinine was similar to previous sessions. Only HET animals exhibited higher latency to
first visit alcohol 8% (0.36 ± 0.3h) compared to ppHcrt KO (0.08 ± 0.05h) and WT mice (0.03
± 0.01h). The latencies to first visit the corner paired with alcohol 16% reached the highest
values indicating that animals manifested a real aversion for the corner paired with alcohol 16%.
Statistical analysis confirmed that the latency to first visit corners was highly dependent on the
liquid solutions available (F(3,272)(liquid solutions)=22.2, p-value<0.001).
The latency to first lick ranged from the few minutes to few hours depending on the liquid
solutions (F(3,272)(liquid solutions)=31.8, p-value<0.001), but was not influenced by the genetic
background (F(2,272)(genotypes)=0.8, p-value>0.05). During the procedure, the latencies to first
lick water reached a few minutes, whereas the latency to first lick the quinine solution reached
hours (figure 4.26b). The latency to lick alcohol 8% and alcohol 16% was similar in session 1
and 2 for all genotypes. On session 3, the latency to first lick alcohol 8% and 16% increased in
ppHcrt KO and WT mice, respectively. During the challenge session, the latency to first lick
water and alcohol 8% was similar in all genotype. WT, KO and HET mice showed increased
latencies to first lick alcohol 16%. Animals of all genotypes did exhibit a robust aversion for
the quinine taste even after two weeks of passive extinction. The development of preference or
aversion was maintained or reinforced during the entire procedure since a significant sessions
effect (F(3,272)(sessions)=31.8, p-value<0.001) was observed. Reduced number of animals per
group explains the high variability of the latency to first lick. Further, a few animals only
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visited the corners without licking quinine or alcohol 16%, whereas other mice chose to taste
every solution, even in very limited amounts.
Introduction of a new liquid solution in the IC
The liquid solutions provided in the IntelliCages influenced the exploratory pattern and the
liquid consumption behaviors of females. All mice displayed an aversion for bitter taste. We
then investigated their sensitivity for sweet taste. During session of 3 consecutive days, quinine
was replaced by 0.2% saccharin and the total number of visits and licks were again monitored
(figure 4.27).
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Figure 4.27: IntelliCages R©: Comparison between quinine and saccharine. Female mice were challenged for both
1mM quinine and 0.2% saccharine in one week interval. The total number of visits (a) and licks (b) of WT (square;
n=7), HET (circle; n=7) and ppHcrt KO mice (triangle; n=6) were measured in the different corners where water
(black), 1mM quinine or 0.2% saccharine (red), alcohol 8% (green) and alcohol 16% (yellow) were provided. The
data are represented as the mean ± SEM. # p-value<0.05 versus alcohol 8%, alcohol 16%, 1mM quinine (quinine
session), water and 0.2% saccharine (saccharine session). $ p-value<0.05 versus water, alcohol 8% (quinine session).
* p-value<0.05 versus water, alcohol 8%, alcohol 16% and 1mM quinine (saccharine and quinine sessions). @ p-
value<0.05 HET versus KO (saccharin session).
Not surprisingly, replacement of quinine by saccharine shifted the amount of visits from the
water corner to the saccharine corner (F(3,136)(liquid solutions)=11.3, p-value<0.001) (figure
4.27a). Only WT and HET mice significantly visited more frequently the corner paired with
saccharine, whereas ppHcrt KO did not. A significant genotype effect (F(2,136)(genotypes)=9.8,
p-value<0.001) was observed. Consequently, the number of visit in the water corner was reduced
in all genotypes relative to the session where quinine was present.
When quinine was available in one of the four corners, animals did show a clear preference
for the corner associated with water (figure 4.27a), and mainly drank water than alcohol (8%
and 16%) (figure 4.27b), with a particular aversion for quinine. In addition, the presence of
saccharin in the IntelliCages blunted consumption of both alcohol solutions (8% and 16%) and
even water (figure 4.28). However, all genotype did exhibit a residual consumption of alcohol 8%
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that was similar to alcohol intake observed when quinine was available (figure 4.29). Noteworthy,
consumption behavior was significantly influenced by genotypes effect (F(2,136)(genotypes)=7.9,
p-value<0.001); KO mice consume significantly less liquid compared to WT and HET littermates
(figure 4.29).
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Figure 4.28: Intellicages R©: Liquid consumption behaviors in females. Female mice were challenged for both 1mM
quinine (1) and 0.2% saccharine (2) in one week interval. The total number of licks of WT (black; n=7), HET (grey;
n=7) and ppHcrt KO mice (white; n=6) was measured in the different corners where water, 1mM quinine or 0.2%
saccharine, alcohol 8% and alcohol 16% were provided. The data are represented as the mean ± SEM. # p-value<0.05
versus alcohol 8%, alcohol 16%, 1mM quinine (quinine session), water and 0.2% saccharine (saccharine session). $
p-value<0.05 versus water, alcohol 8% (quinine session). * p-value<0.05 versus water, alcohol 8%, alcohol 16% and
1mM quinine (saccharine and quinine sessions). @ p-value<0.05 HET versus KO (saccharin session).
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Figure 4.29: Intellicages R©: Detailed liquid consumption behaviors in females. Female mice were challenged for
both 1mM quinine (1) and 0.2% saccharine (2) in one week interval. The total number of licks of WT (black; n=7),
HET (grey; n=7) and ppHcrt KO mice (white; n=6) was measured in the different corners where water, 1mM quinine
or 0.2% saccharine, alcohol 8% and alcohol 16% were provided. The data are represented as the mean ± SEM. #
p-value<0.05 versus alcohol 8%, alcohol 16%, 1mM quinine (quinine session), water and 0.2% saccharine (saccharine
session). $ p-value<0.05 versus water, alcohol 8% (quinine session). * p-value<0.05 versus water, alcohol 8%, alcohol
16% and 1mM quinine (saccharine and quinine sessions). @ p-value<0.05 HET versus KO (saccharin session).
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After normalization of previous data collected in the IntelliCages R©, we observed an attenu-
ation of the differences between WT, HET and ppHcrt KO animals. Here, again the amounts of
visits and licks in each corner were reported to the total number of visits and licks, respectively,
for each genotype.
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Figure 4.30: IntelliCages R©: Comparison between quinine and saccharine. Female mice were challenged for both
1mM quinine and 0.2% saccharine in one week interval. The proportions of visits (A) and licks (B) of WT (square;
n=7), HET (circle; n=7) and ppHcrt KO mice (triangle; n=6) were measured in the different corners where water
(black), 1mM quinine or 0.2% saccharine (red), alcohol 8% w/v (green) and alcohol 16% w/v (yellow) were provided.
The data are represented as the mean ± SEM. # p-value<0.05 versus alcohol 8%, alcohol 16%, 1mM quinine (quinine
session), water and 0.2% saccharine (saccharine session). $ p-value<0.05 versus water, alcohol 8% (quinine session).
* p-value<0.05 versus water, alcohol 8%, alcohol 16% and 1mM quinine (saccharine and quinine sessions).
The proportion of visits was significantly higher for the water corner compared to other
corners in presence of quinine (figure 4.30a), an observation that was not that clear cut on
figure 4.27a. After replacement of quinine by saccharine, all animals exhibited a significant
preference for the corner paired with saccharine relative to the other corners (F(3,136)(liquid
solutions)=53.5, p-value<0.001). The proportion of visits in the water corner was decreased
in favor of the saccharine corner. Interestingly, no genotypes effect was observed; ppHcrt KO,
HET andWT exhibited similar exploration pattern (F(2,136)(genotypes)=5.5e-17, p-value>0.05).
All females displayed a strong preference for water relative to alcohol solutions (8% and
16%) and a robust aversion for quinine (F(3,136)(liquid solutions)=116.0, p-value<0.001) (figure
4.31). All mice did drink alcohol 8% and to a lower extent alcohol 16% (figure 4.32). In the
presence of saccharine, all animals significantly exhibited a preference for the sweetened solution
and drastically reduced the proportion of licks for water, alcohol 8% and 16%. Interestingly, all
genotypes did exhibit similar consumption behavior, no statistical differences with our sample
size were observed between genotypes (F(2,136)(genotypes)=0.06, p-value>0.05), once the licking
behavior in one corner was compared to the total number of licks (all corners included).
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Figure 4.31: Intellicages R©: Liquid consumption behaviors in females. Female mice were challenged for both
1mM quinine and 0.2% saccharine in one week interval. The proportions of licks of WT (black; n=7), HET (grey;
n=7) and ppHcrt KO mice (white; n=6) were measured in the different corners where water, 1mM quinine or 0.2%
saccharine, alcohol 8% and alcohol 16% were provided. The data are represented as the mean ± SEM. # p-value<0.05
versus alcohol 8%, alcohol 16%, 1mM quinine (quinine session), water and 0.2% saccharine (saccharine session). $
p-value<0.05 versus water, alcohol 8% (quinine session). * p-value<0.05 versus water, alcohol 8%, alcohol 16% and
1mM quinine (saccharine and quinine sessions).
4. RESULTS 78
Pr
o
po
rti
on
 o
f l
ic
ks
 (m
ea
n ±
 se
m)
WT KO HET WT KO HET
1mM Quinine 0.2% Saccharine
available in IC available in IC
0.0
0.2
0.4
0.6
0.8
1.0
# #
#
Water
Pr
o
po
rti
on
 o
f l
ic
ks
 (m
ea
n ±
 se
m)
WT KO HET WT KO HET
1mM Quinine 0.2% Saccharine
available in IC available in IC
0.0
0.2
0.4
0.6
0.8
1.0
$
*
$
*
$
*
1mM Quinine or 0.2% Saccharine
Pr
o
po
rti
on
 o
f l
ic
ks
 (m
ea
n ±
 se
m)
WT KO HET WT KO HET
1mM Quinine 0.2% Saccharine
available in IC available in IC
0.0
0.1
0.2
0.3
0.4
Alcohol 8%
Pr
o
po
rti
on
 o
f l
ic
ks
 (m
ea
n ±
 se
m)
WT KO HET WT KO HET
1mM Quinine 0.2% Saccharine
available in IC available in IC
0.00
0.05
0.10
0.15
0.20
Alcohol 16%
Figure 4.32: Intellicages R©: Detailed liquid consumption behaviors in females. Female mice were challenged for
both 1mM quinine and 0.2% saccharine in one week interval. The proportions of licks of WT (square; n=7), HET
(circle; n=7) and ppHcrt KO mice (triangle; n=6) were measured in the different corners where (a) water, (b) 1mM
quinine or 0.2% saccharine, Aˆ c© alcohol 8% and (d) alcohol 16% were provided. The data are represented as the mean
± SEM. # p-value<0.05 versus alcohol 8%, alcohol 16%, 1mM quinine (quinine session), water and 0.2% saccharine
(saccharine session). $ p-value<0.05 versus water, alcohol 8% (quinine session). * p-value<0.05 versus water, alcohol
8%, alcohol 16% and 1mM quinine (saccharine and quinine sessions).
5 Discussion
The hypothalamus is an important mediator of reward-related and motivational behaviors.
LH lesions led to a reduced motivation for pleasurable stimuli and electrical intracranial self-
stimulation of the LH is powerfully rewarding for humans and for rodents. The identification
of novel neuropeptidergic pathways originating from the LH, such as Hcrt, has given new in-
sights in the function of LH neurons. Growing evidence shows that Hcrt have implications in
drug-related behaviors. However, only a few reports used constitutive ppHcrt KO mice to study
addictive behaviors. This current report aimed at better understanding the functional role of the
hypocretin system in alcohol- and cocaine-related behaviors. Several experimental procedures
were used to assess alcohol- and cocaine-related behaviors in WT, HET and ppHcrt KO mice
from both gender.
5.1 Behavioral sensitization
5.1.1 Behavioral sensitization in males
Constitutive ppHcrt KO mice and their littermates were first tested using the classical locomotor
sensitization paradigm, which assesses the pharmacological property of psychostimulant drugs.
In the present work, we observed that WT, HET and KO males exhibited a cocaine-induced
locomotor sensitization in an openfield. However, the ppHcrt KO mice showed a significant de-
layed and attenuated cocaine-induced behavioral sensitization compared to WT mice, which is
in agreement with previous observations reported either with HcrtR1 antagonist (SB-334867) or
with constitutive ppHcrt KO mice treated with morphine, methamphetamine, methylphenidate
and MDMA [204, 217]. Interestingly, HET mice, which express reduced Hcrt-1 and Hcrt-2
peptide levels, exhibited an intermediate behavioral sensitization pattern. To our knowledge,
this is the first study assessing behavioral sensitization in HET animals. These data suggest
that when preprohypocretin is downregulated or absent or when the hypocretin receptor 1 is
blocked, animals display an impaired drug-induced locomotor response to psychostimulants and
opioids [200,204,218]. However, we observed that when the distance traveled within the first 15
min following cocaine treatment was normalized to the 15 min of habituation, the differences
between KO, HET and WT were minimized. Indeed, all mice did demonstrate similar amplitude
in behavioral sensitization following daily cocaine treatment, except following the first cocaine
session during which a significant difference was noticed between KO and WT mice. Sharf et
al. [216] and Georgescu et al. [279] already reported very limited difference between KO and
WT mice following chronic intermittent morphine treatment.
Constitutive ppHcrt KO males exhibit a reduced cocaine-induced behavioral sensitization.
In the literature, a few transgenic mice exhibit hypoactivity and reduced behavioral sensitization
following repeated psychostimulant or opioid exposures. Dopamine deficient mice, for example,
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also display an attenuated locomotor sensitization [49, 50]. In addition, pharmacological treat-
ment with D1 or D2 receptor antagonists in WT animals did suppress locomotor response to
psychostimulant and opioid drugs [280]. It has been demonstrated that the hypocretin system
anatomically and functionally interacts with the dopaminergic system [197]. And impairment of
the dopamine neurotransmission leads to dyskinesis. Hypocretin containing neurons send strong
projections to the VTA which, in turn, sends projections to the NAcc [78] playing a key role
in the striato-nigro striatal spiraling connection [211] regulating the locomotor activity. Activa-
tion of the NAcc is critical for the development of behavioral sensitization. Cocaine blocks the
dopamine, noradrenalin and serotonin transporters thus enhancing monoaminergic concentra-
tions in the synaptic cleft [281, 282]. Increasing DA release in the NAcc induces the activation
of D1 dopamine receptors responsible for long term modification in this region and therefore
the development of sensitization [47]. It has been observed that hypocretin neurons are highly
active during locomotor activity [283]. Direct application of the hypocretins into the VTA in-
duces DA release in the VTA, but also in the PFC and NAcc [180,204]. Blockade of the HcrtR1
in the VTA or constitutive hypocretin deficient mice showed reduced DA release [217, 227]. In
addition, constitutive ppHcrt KO mice express low DA ratio and elevated serotonin metabolites
and ratio in the medial PFC compared to WT [217]. In addition, administration of hypocretins
induces hyperlocomotion in rodents and pretreatment with D1 or D2 dopamine receptor an-
tagonists [204], but not serotonin receptor antagonists [284], abolished the hypocretin-induced
locomotor activity. Since hypocretin producing neurons interact anatomically and functionally
with the mesolimbic structures and since constitutive ppHcrt KO mice express low level of DA
in the medial PFC, it is possible that hypocretins deficiency lead to impaired DA system.
Drugs of abuse not only act through the dopaminergic system, but also through the glu-
tamatergic system. NMDA receptor-deficient mice do also exhibit attenuated cocaine-induced
locomotor activity [42, 285, 286]. In addition, blockade of NMDARs and AMPARs blunted
drug-induced hyperlocomotion in WT animals. Cocaine treatments induce long term changes
in glutamatergic transmission in the VTA through the induction of NMDAR-dependent LTP
which is thought to modify AMPAR function and number [39]. It has been reported that in vitro
application of hypocretins in the VTA induces changes in glutamate transmission and especially
at the receptor level through NMDARs and AMPARs [200,201]. Treatments with Hcrt-1 and/or
Hcrt-2 peptides potentiate NMDARs EPSCs current and stimulate subunits reorganization and
translocation to the synapses [200]. Hcrt-1, but not Hcrt-2, treatment also modulates late
phase AMPARs expression and function which facilitates cocaine-mediated responses [200,201].
Cocaine treatments upregulate cell surface expression of AMPARs [287] and upregulate the ex-
pression levels of HcrtR2, but not those of HcrtR1, in NAcc [288]. And application of Hcrt-1 in
the striatum also mediates an increase in AMPARs cell surface expression [212]. Hence, most
likely Hcrt deficiency alters glutamate receptors expressions and thus behavioral sensitization.
Behavioral sensitization is the result of multiple concomitant actions in distinct brain regions
occurring from the very first cocaine use [39]. Low expression levels or Hcrt deficiency might al-
ter drug-induced response through the dopaminergic and glutamatergic systems. Both systems
5. DISCUSSION 81
target the NAcc and concomitant activation of the dopamine and glutamate signaling pathways
induce neuronal plasticity. It receives strong input from the VTA and, in turn, sends strong pro-
jections to hypocretin producing neurons which innervate the VTA. Together these observations
suggests that the VTA, the NAcc and the LH interact closely. In addition, intact dopaminergic,
glutamatergic and hypocretinergic systems are necessary to trigger normal drug-induced hy-
perlocomotion. Constitutive ppHcrt KO mice did also exhibit delayed behavioral sensitization
regarding the distance traveled in the one hour testing session, suggesting that the processes are
partially independent of hypocretins, but hypocretins facilitate its development and expression
from the first cocaine exposure. The hypocretin system seems to be a relay between the VTA
and the NAcc for promoting potentiation of drug-induced response. The impairment in basal
locomotor activity and the development of sensitization induced by the first cocaine treatment
observed in rodents treated with pharmacological antagonist of the hypocretin receptor 1 or in
constitutive ppHcrt KO might occur through the concomitant impairment of DA release and
neuronal plasticity [289].
5.1.2 Behavioral sensitization in females
In openfield
The hypocretinergic system is age- and gender-dependent [62]. It has been observed that WT
females have higher levels of preprohypocretin mRNA and peptides compared to males, and
also higher hypocretin receptors mRNA levels [62, 84, 290]. In addition, gender differences were
already reported in behavioral sensitization to psychostimulants [291].
In order to determine whether gender could affect cocaine-related behaviors, KO, HET and
WT females were also tested in an openfield for assessing locomotor sensitization. Surprisingly,
we observed that KO, HET and WT exhibited similar cocaine-induced behavioral sensitization.
In agreement with previous results with morphine [216], our observations suggest that cocaine-
induced behavioral sensitization is hypocretin-independent in females since their absence did
not alter behavioral response to chronic treatment with psychostimulant. We hypothesized pre-
viously that the basal locomotor activity and the attenuated drug-induced hyperlocomotion in
males could be due to an alteration of the DA and glutamate systems. However, this hypothesis
does not match with the results obtained in females, as no overt difference was observed between
genotypes, even following the first cocaine injection. In addition, comparison between males and
females data did not highlight any significant gender effect. Nevertheless, it has been reported
that dopamine level is also gender-dependent and female hormones modulate DA activity in
the NAcc and the striatum [292]. One possible hypothesis is that estrogen and progesterone,
two hormones also present in the hypothalamus, might compensate the lack of hypocretins and
thus maintain the appropriate basal levels of dopamine. However, Mori et al. [217] only look at
DA levels in males. So far, no data were found in the literature with regards to monoamines
expression in ppHcrt KO females only.
Neuropeptides involved in feeding behavior have also the potency to facilitate drug-induced
behavioral sensitization. Furthermore, numerous reports indicated that leptin or insulin did
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influence drugs of abuse consumption [293]. Interestingly, ppHcrt KO females have higher lep-
tins levels relative to ppHcrt KO males and WT animals [294]. And it has been observed that
leptin facilitates psychostimulant behavioral sensitization through activation of the mesolimbic
circuit [295,296]. Leptin-deficient mice exhibit blunted locomotor sensitization to psychostimu-
lant, however when rescued with leptin infusions, animals exhibited normal locomotor sensitiza-
tion [297]. KO females might compensate the lack of hypocretins with higher levels of leptin and
maintain the appropriate neuronal activity for normal behavioral response to psychostimulants.
Little was reported on hypocretin deficient females and many reports did not mention any
major differences between males and females. Here, we reported that, in contrast to males,
hypocretins are not necessary in female mice for the development and expression of cocaine-
induced locomotor sensitization.
In running wheel
Animals tested in a large circular arena might be stressed and might produce cross sensitiza-
tion between stress and psychostimulant responses. Thus, the hyperlocomotion observed in KO
females following cocaine exposure might not only result from the activation of the dopamine
circuit only, but also from the brain stress pathways [298].
Other groups of KO, HET and WT littermates were tested in smaller cages equipped with
running wheels. Wheel running is an alternative measurement of voluntary locomotor ac-
tivity. Moreover, it has been reported that wheel running augments drug-induced sensitiza-
tion [299–301]. In this paradigm, we observed that the distance traveled by hypocretin deficient
mice was shorter compared to HET and WT animals during the entire procedure. However,
following repeated psychostimulant exposures, ppHcrt KO mice did exhibited behavioral sensi-
tization similar to that observed in HET and WT mice. This observation suggests that ppHcrt
KO mice might display locomotor deficiency. Although no statistical difference was observed,
KO females tended to exhibit more difficulty to adjust movements to speed in the running wheel
compared to HET and WT animals.
5.1.3 Coordination deficiency at high speed in ppHcrt KO females
KO mice, HET and WT littermates were tested on rotarod in order to assess movement coordi-
nation. We observed that ppHcrt KO and HET mice exhibited coordination deficiency at high
speed compared to WT. This result was consistent with results obtained with the running wheel
paradigm; both experiments demonstrated impaired locomotor activity in mutant mice. These
observations were masked by locomotor sensitization in the openfield. These results suggest that
hypocretin peptides are necessary for an efficient movement coordination. Hypocretin deficiency
may triggered lower dopamine release level in the ventral part of the striatum which might induce
a weaker response of the motor cortex and therefore may impair motor control. In addition, it
has been reported that running wheel promotes wakefulness and cataplexy attacks in ppHcrt KO
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mice [302] possibly responsible for the reduced distance traveled in comparison with HET and
WT animals. Positive emotions may trigger cataplexy in mice, just as in narcoleptic patients.
Cocaine treatment may induce positive affects in rodents. Ultrasonic vocalizations provide in-
sight into the affective state of animals. 22-kHz calls occur in the presence of aversive events,
while 50-kHz calls are linked with anticipatory and appetitive outcomes. Ultrasonic vocaliza-
tions likely coincides with cocaine self-administration and 50-kHz frequency calls were observed
in rats trained to self-administer high dose of cocaine [303]. Noteworthy, most of patients with
narcolepsy-cataplexy are treated with psychostimulants, such as amphetamine or amphetamine-
like drugs. Psychostimulants are wake-promoting substances used for the treatment of excessive
daytime sleepiness in narcoleptic patients and have minimal effect on cataplexy [304]. In the
present report, ppHcrt KO mice were treated with 15mg/kg of cocaine which may produce posi-
tive emotions. Since positive emotions and wheel running promotes cataplexy attacks in ppHcrt
KO and cocaine treatments did not reduce cataplexy symptoms [302,305], it is most likely that
cocaine may induce several cataplexy attacks in running wheels and thus supports the reduced
distance traveled in KO mice.
5.2 Cocaine rewarding properties in ppHcrt KO mice
The rewarding and reinforcing properties of cocaine in ppHcrt KO, HET and WT mice was then
assessed with the help of the conditioned place preference paradigm, which provides indirect
measurement of drug seeking behaviors. It has been reported that females and males differ-
entially express preprohypocretin mRNA and peptides, as well as different hypocretin receptor
levels [62, 84, 290]. However, we observed that all mice, whatever their gender and genotype,
did exhibit similar conditioned place preference for the context paired with repeated cocaine
injections, which is consistent with previous reports [216]. In line with the data obtained in
the locomotor sensitization paradigm, we confirmed the reduced locomotor activity in male and
female KO mice during the pre- and post-conditioning sessions. The preference for the environ-
ment previously paired with drug reward has been reported to persist for up to four weeks in
WT rodents [276,277]. Here, we confirmed that both WT and HET animals (males and females)
still displayed a significant place preference for the compartment paired with repeated cocaine
administration, whereas ppHcrt KO mice stopped expressing a preference two weeks after the
last cocaine injection. Hence the long term maintenance of the preference for the compartment
previously paired with cocaine might depend on the hypocretin system.
This finding is in line with the attenuated morphine withdrawal observed in ppHcrt KO
mice [279] or in WT mice treated with SB-334867 [306]. Morphine withdrawal produces acute
activation of Hcrt cells and especially the Hcrt gene demonstrating the regulation of Hcrt neurons
by chronic morphine and morphine withdrawal [279]. Hcrt action through HcrtR1 contributes
to the expression of the withdrawal symptoms [306]. The attenuation of morphine withdrawal
behaviors in ppHcrt KO mice or in SB-334867 treated WT animals implies that the Hcrt system
serves an important functional role in modulating responses to drugs of abuse. The projections
of Hcrt neurons and their interactions with dopaminergic systems suggest a potential pathway
that may be implicated in Hcrt modulation of morphine withdrawal [104, 197]. Analysis of c-
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Fos expression suggests that the NAcc shell may be a critical region in mediating this effect [306].
The normal development of conditioned place preference also depends on mesocortical cir-
cuitry. The association between the context and the effect induced by psychostimulant admin-
istration is mediated by the activation of mesolimbic brain structures [196]. Positive or negative
sensory stimuli induced by drugs of abuse treatment affect the amygdala, the hippocampus
and the PFC which all mediate the association between the context and drugs of abuse treat-
ment contingency. All these sites are important in the development and the maintenance of
conditioned place preference. Lesions of the amygdala or the PFC affect the reinstatement of
extinguished preference for the context previously associated with repeated cocaine administra-
tion [307, 308]. On the other hand, lesions of the dorsal hippocampus alter the acquisition and
expression, but not the consolidation of cocaine conditioned place preference [309]. As previ-
ously mentioned the hypocretin system is closely connected to mesolimbic structures; it sends
strong projections and receives dense afferents from the amygdala, the cerebral cortex and, to
a lower extent, from the hipppocamus and the VTA. Hypocretin producing neurons might act
as a regulatory relay facilitating the synchronization of different neuronal populations in order
to promote the appropriate response, for instance triggering phasic firing of dopamine neurons
known to play a key role in behavioral conditioning [47, 48]. The lack of Hcrt may not alter
the development of CPP, since KO mice showed normal place preference, but hypocretin defi-
ciency may attenuate the long-term maintenance of the conditioned preference since KO mice
stopped expressing the place preference after a two weeks of passive extinction. Hence, the as-
sociation between the context and the rewarding properties of cocaine may not have been that
robust in KO mice compared to HET and WT littermates. This hypothesis is consistent with
recent findings according to which narcoleptic patients failed to exhibit any increased activity
in the amygdala in response to conditioned stimuli [310]. In addition, it has been reported that
rats treated with the HcrtR1 antagonist SB-334867 have impaired cue and context driven drug
seeking behavior [233]. Since context driven relapse to drug seeking requires intact dorsolat-
eral striatum [311], and since the dorsal striatum is crucial for drug seeking habits [312], the
deficiency of hypocretins might affect the functioning of the dorsal striatum by interfering with
inputs from the amygdala, the hippocampus and the PFC.
Noteworthy, dopamine is not the only monoaminergic system that could mediate condi-
tioned place preference. Indeed dopamine deficient mice display normal conditioned place pref-
erence possibly through serotonin signaling [313]. Constitutive ppHcrt KO mice showed reduced
dopamine levels and higher basal serotonin ratio relative to WT [217]. The hypocretin system
sends dense fibers into the raphe [73] considered to be the main source of serotoninergic neurons
in the brain [314]. In addition, cocaine treatment inhibits the reuptake of serotonin leading to
overstimulation of the NAcc through activation of serotonin receptors [281,282]. 5-HT1A recep-
tors have a wide CNS distribution and contribute to the regulation of many behaviors, such as
locomotor activity, feeding behaviors, grooming, anxiety, sleep/wake cycles and reward-related
behaviors. 5-HT1A receptor agonists facilitate behavioral sensitization to psychostimulant drugs,
whereas antagonists attenuate its expression [315,316]. Furthermore, 5-HT1A receptors mediate
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conditioned place preference [317]. Application of serotonin on hypocretin neurons induces hy-
perpolarization through 5-HT1A receptors [318]. Hence, ppHcrt KO animals might compensate
the reduced DA response to psychostimulant with an increased activation of the serotoninergic
system.
Together, these observations suggest that in ppHcrt KO mice, the NAcc might integrate inap-
propriately dopamine and serotonin signaling and might induce inappropriate signaling through
the serial dopamine striato-nigro-striatal connection, resulting in an altered activation of the
dorsal striatum and an impaired transition from goal directed behavior to drug seeking habits.
In brief, it seems that developmental neuronal adaptations occurring in ppHcrt KO mice may
compensate the lack of hypocretins for promoting normal conditioned place preference, but not
its maintenance over time. Further studies are needed to assess this hypothesis.
5.3 Drinking behaviors in ppHcrt KO female mice
Finally, we assessed the ability to drink alcohol in WT, HET and KO mice. The IntelliCage is a
novel apparatus that permits individual monitoring in social groups (up to 12 mice). The Intel-
liCages could provide indirect measurement of circadian rhythm [319]. Thus, total numbers of
visits, nosepokes and licks, as well as their respective duration, are collected over time. We were
able to show that ppHcrt KO mice displayed similar circadian visiting pattern compared to HET
and WT littermates with higher amounts of visit during the dark phase and lower amounts dur-
ing the light phase. It has been reported that ppHcrt KO mice exhibit an impaired sleep/wake
rhythm with narcoleptic-like phenotype and cataplexy attacks. We have not observed any dif-
ference in the amounts of visits between genotypes during the first two days of habituation.
Licking pattern was also hourly assessed and showed a similar circadian rhythm. Noteworthy,
ppHcrt KO mice did show significantly reduced amounts of licks for water compared to WT and
HET animals. KO, HET and WT mice were then challenged with four different solutions, water,
1mM quinine, alcohol 8% and 16%. We report here a trend for reduced amounts of visits and
licks in KO compared to WT and HET animals, confirming a hypoactive phenotype although
our sample size did not permit the identification of any significant differences.
Similarly to the behavioral sensitization, when the data were standardized, the proportion
of visits and licks in the KO group was identical to values observed in the WT group. Animals
preferred visiting and licking at the water corner at the expense of other corners. The propor-
tion of visits in the other corners was similar between genotypes. The corner associated with
alcohol 16% was apparently aversive for all mice since they displayed very low amounts of visits
similar to those observed for the corner associated with 1mM quinine. We also noticed that KO,
HET and WT mice spontaneously drink alcohol 8%, since the proportion of licks for alcohol 8%
was higher compared to quinine and alcohol 16%. Surprisingly, although all animals displayed
a strong aversion for drinking quinine, they visited frequently for this corner compared to the
alcohol 16% corner. These observations are consistent with data found in literature where mice
avoid bitter taste and high alcohol concentrations.
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It has been observed that the olfactory bulb receives dense fibers of hypocretin system [79]
and the lack of hypocretins in human alter the olfactory sense which could be rescued by in-
tranasal application of synthetic hypocretins [320]. The possibility that ppHcrt KO mice might
have impaired gustatory sense is not supported here since the latency to first lick aversive liquid
solutions (1mM quinine or alcohol 16%) increased over sessions suggesting that all genotypes
learned to discriminate liquid solutions.
Following two weeks of alcohol abstinence, individuals of all genetic background, did not
exhibit any rebound in alcohol drinking behavior. The proportion of licks for alcohol 8% tended
to decrease in ppHcrt KO mice compared to WT and HET mice, but this difference was not
statistically significant in our sample size. This latter observation could be related to the ab-
sence of persistent preference for the cocaine compartment after a two-week period of passive
extinction in KO mice.
When quinine was replaced with saccharine, WT and HET, and to a much lower extent
ppHcrt KO mice, drastically shifted their visits and licks activity toward the corner paired with
saccharine. WT and HET and to a lesser extent KO mice preferred visiting and drinking at
the saccharine corner rather than water and alcohol (8% and 16%). After standardization of
the data, the proportion of visits and licks in the KO group was similar to the WT group. All
animals preferred visiting and licking at the saccharine corner and strongly neglected the other
corners. The proportion of visits and licks in the other corners was similar between genotypes.
This support the idea that, in our sample size, KO mice exhibit a hypoactive phenotype which
is responsible for the reduced sweet solution consumption.
The lateral hypothalamus has been implicated in alcohol seeking behaviors. A robust ex-
pression of hypocretins mRNA following acute alcohol exposure was observed, whereas chronic
exposure suppresses hypocretin expression [278]. This suggests that the lack of hypocretin might
impaired alcohol consumption. However, in the present study, spontaneous alcohol intake in KO,
HET and WT mice was barely different suggesting that the hypocretin system is most likely
involved in the operant conditioning associated with alcohol intake, rather than being involved
in the regulation of alcohol intake per se.
Since the lack of hypocretin did not drastically alter spontaneous alcohol consumption, it
suggests that alternative pathways might compensate the hypocretin deficiency. It is also notable
that Hcrt cells release the endogenous opioid peptide dynorphin [321]. It remains to be deter-
mined whether the role of this neuropeptide has functional implications for alcohol consumption
in constitutive ppHcrt KO. Further, the lateral hypothalamus also hosts the MCH system that
does regulate alcohol consumption [267, 268, 272, 273] and interacts with Hcrt [274, 275]. When
MCH is microinjected directly in the brain, it increases alcohol intake in a dose dependent man-
ner and MCHR antagonists dose dependently suppress alcohol consumption [267,268,272,273].
High alcohol intake reduces significantly MCH mRNA levels. An increase activity in the MCH
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system might compensate Hcrt deficiency and might promote spontaneous alcohol drinking, but
further studies are needed to assess this hypothesis.
5.4 Further considerations
We used constitutive ppHcrt KO mice, HET and WT littermates issued from HET crosses to
assess reward related behaviors. Only the gene coding for the ppHcrt is disrupted in KO mice,
therefore neurons are still present, but do not express the functional hypocretin peptides. The
hypocretin-producing neurons do not only express hypocretins, but also other neuropeptides,
such as dynorphin [321] or neuropeptide S [322,323], which are known to modulate reward seeking
behaviors. Hypocretin-deficient mice show abundant prodynorphin mRNA in the LH [321]and
compensations of the hypocretins deficiency is most likely occurring in this strain. The lack of
hypocretin was also shown to interfere with the expression of peripheral peptides, such as leptin
which is upregulated in ppHcrt KO mice [294]. The LH densely expresses leptin receptor and di-
rect leptin application regulates gene expression in Hcrt neurons. In addition, the MCH system,
the LH second neuronal population, directly interact with the Hcrt system [274,275] and share
several similarities. Both are required for the regulation of many physiological processes, such as
arousal, feeding behaviors and reward-related behaviors. Since both neuronal populations trig-
ger common outcomes, the MCH system may counterbalance the absence of hypocretin peptides
in order to relay the necessary signaling to cortical structures to maintain the required level of
arousal for orchestrating appropriate copying strategies and responses to environmental demands
and basic metabolic needs. These suggest that constitutive ppHcrt KO mice may have developed
several adaptations for counterbalancing various dysfunction in metabolic or cognitive processes.
6 Conclusion & Perspective
The present work emphasized the role of the hypocretin system in the regulation of reward
seeking behaviors. We used transgenic mice model issued from HET crosses challenged them
with cocaine and alcohol using classical paradigms.
Considering rough data, it is evident that Hcrt deficient males and to a lower extent females
displayed a hypoactive phenotype which could be related to impaired mesolimbic structures.
This could account for delayed locomotor sensitization compared to WT littermates. Neverthe-
less, after data standardization, ppHcrt KO still exhibited rewarding effect suggesting that these
mice may have undergone major neurocircuitry adaptations leading to normal reward seeking
behaviors.
Indeed, all mice exhibited a robust conditioned place preference for cocaine. Noteworthy,
after two weeks of cocaine abstinence, KO males and females, no longer displayed preference for
the compartment previously paired with repeated exposures to cocaine, whereas WT and HET
mice continued expressing the place preference. This observation suggests that the development
of behavioral conditioning is independent of hypocretins, but the maintenance of such condi-
tioning may require an intact Hcrt system. Impaired connectivity or reduced strength signaling
between the amygdala, the hippocampus and the PFC may be occurring in Hcrt deficient mice.
The ppHcrt KO mice exhibited a circadian rhythm regarding visits and licks in the Intel-
liCages. When four different liquid solutions were provided, we observed a reduced trend in
ppHcrt KO mice considering the amount of visits and licks relative to HET and WT. After
data standardization, all mice did exhibit similar exploratory and drinking behaviors with a
strong preference for water and aversion for quinine. Following two weeks of alcohol abstinence,
ppHcrt KO mice, HET and WT littermates did not display any rebound for alcohol drinking.
No difference was observed between genotypes regarding the proportion of visits and licks for a
sweet solution. However, the ppHcrt KO mice hypoactivity did affect the total number of visits
and licks to the saccharine corner.
Here, we report that only cocaine-related behaviors are partially impaired in Hcrt deficient
mice. In contrast, KO mice barely displayed any behavioral changes but a trend for reducing
sweet and alcoholic beverages. The ppHcrt KO line may compensate the absence of hypocretins
by other neuropeptides. To date, no deep investigations were performed on the molecular con-
tent of hypocretins neurons neither in WT nor in ppHcrt KO mice. In literature, little is known
regarding neuronal plasticity in ppHcrt KO mice following repeated exposures to psychostimu-
lant drugs. Thus, molecular investigations (microdialysis, qPCR, microarray) are necessary to
further discuss cellular and molecular adaptations in these mice.
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